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THE ROLE AND MECHANISM OF THE HOMEOBOX GENE HOXA9 IN THE GROWTH 
OF EPITHELIAL OVARIAN CANCER 
 
Song Yi Ko, Ph.D. 
Supervisory Professor: Honami Naora, Ph.D. 
 
 
Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer death among 
women in the United States. The high lethality of EOCs stems from rapid peritoneal 
involvement. EOCs frequently colonize peritoneal surfaces that overlie connective and 
adipose tissues. However, the mechanisms that enable ovarian cancer cells to readily 
adapt to the peritoneal environment are poorly understood. HOXA9, a homeobox gene that 
is normally expressed in the developing female reproductive tract, is aberrantly expressed 
in EOCs and controls the morphologic features of these tumors. The differentiation pattern 
of a tumor is an important determinant of its clinical behavior and prognosis. The overall 
goal of this project is to determine the clinical significance of HOXA9 and its mechanisms in 
the biological behavior of EOC. In this study, I demonstrated that expression of HOXA9 is 
strongly associated with poor outcomes in EOC patients and in mouse xenograft models of 
EOC. Whereas HOXA9 promoted EOC growth in vivo, HOXA9 did not stimulate 
autonomous tumor cell growth in vitro. On the other hand, HOXA9 was found to be 
associated with increased abundance of cancer-associated fibroblasts (CAFs) in mouse 
xenograft models of EOCs and with a CAF-like gene signature in human tumors. However, 
HOXA9 did not induce CAF-like features in EOC cells. Expression of HOXA9 in EOC cells 
induced normal adipose and bone marrow-derived mesenchymal stem cells (MSCs) as well 
as normal peritoneal fibroblasts to express markers of CAFs and to stimulate growth of 
EOC and endothelial cells. These effects of HOXA9 were due in substantial part to its 
vi 
 
transcriptional activation of TGF-β2 that acted in a paracrine manner on peritoneal 
fibroblasts and MSCs to induce CXCL12, IL-6 and VEGF-A expression. These results 
demonstrate that HOXA9 promotes progression of EOC by ‘educating’ the stroma to 
become permissive for tumor growth.  
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CHAPTER 1: INTRODUCTION 
 
A. BIOLOGY OF EPITHELIAL OVARIAN CANCERS (EOCs) 
 
1. Clinical significance of EOCs 
 
 Ovarian cancer is the most common cause of death among women with gynecologic 
malignancy in the United States.1 Ovarian cancers can arise from three ovarian cell types; 
epithelial cells, stromal endocrine cells, and germ cells. More than 90% of malignant 
ovarian cancers are epithelial ovarian cancers (EOCs).2 Traditionally it has been believed 
that EOCs are originated from ovarian surface epithelium or inclusion cysts. Recently, the 
fallopian tube has been reported as an origin of some EOCs.3, 4 EOCs are categorized by 
stage, which describes how far the cancer has spread, and by grade which indicates how 
malignant the cancer is (Table 1).5 Because of the lack of distinctive symptoms and reliable 
biomarkers, most EOC patients are diagnosed with late stage disease. Although more than 
90% of EOC patients who have ovarian-confined disease (stage I) survive five years after 
diagnosis, more than 60% of EOC patients are diagnosed at an advanced stage and only 
30% of these advanced stage patients will survive five years after diagnosis (Table 2).2 
Despite therapeutic advances, the optimal first-line treatment in EOCs is surgical debulking 
and several cycles of intravenous or intraperitoneal chemotherapy with carboplatin and 
paclitaxel. However, most patients with advanced disease ultimately relapse and recurrent 
EOCs tend to be resistant to therapy. Identification of biomarkers for early detection is 
clearly critical to improve survival of EOC patients, but currently available biomarkers for 
EOCs are very limited. The most commonly used marker for EOCs is serum CA-125. Since 
elevated serum CA-125 level is detected in more than 80% of patients with advanced EOC,  
2 
 
Table 1. The International Federation of Gynecology and Obstetrics (FIGO) grading 
and staging system for EOCs5 
  
FIGO system Characteristics 
Grade 
 
1 Well-differentiated (<5% solid growth within a tumor) 
2 Moderately-differentiated  (5 to 50% solid growth within a tumor) 
3 Poorly-differentiated (>50% solid growth within a tumor) 
Stage I Disease confined to the ovaries 
II Disease spread confined to the pelvis 
III Disease confined to the abdominal cavity, including surface of 
the liver, omentum or bowel 
IV Spread to liver parenchyma, lung, or other extra-abdominal sites 
3 
 
Table 2. Stage distribution and 5-year relative survival by stage at diagnosis  
     (for 2003-2009) 2 
 
FIGO stage Stage distribution (%) 5-year relative survival (%) 
Stage I 22.1 89.3 
Stage II 7.8 65.5 
Stage III 35.3 33.5 
Stage IV 31.7 17.9 
Unknown 3.1 29.5 
  
4 
 
it has been routinely used for initial diagnosis of EOC and also for monitoring the response 
to treatment.6,7  However, it has low sensitivity for the diagnosis of early EOCs. In addition, 
it is not specific for EOCs. Serum CA-125 will also be increased with various benign 
conditions such as endometriosis as well as other types of cancers including endometrial 
and pancreatic cancers.8  
 
2. Dissemination of EOCs 
 
 EOCs have a unique pattern of dissemination that differs from classic metastasis of 
other epithelial tumors. Unlike many other epithelial tumors, EOC rarely spreads via the 
vasculature.9 Although EOC can initially spread by directly extending to adjacent organs 
(e.g. fallopian tubes and uterus), most EOCs spread by intraperitoneal seeding (Figure 1).9, 
10 Initially, EOCs are limited to one or both ovaries within the intact ovarian capsule. Once 
the ovarian capsule is disrupted, tumor cells are passively exfoliated by the flow of 
peritoneal fluid. Tumor cells are transported by the circulating peritoneal fluid throughout the 
peritoneal cavity and then implant at secondary sites. Major implantation sites are the 
omentum, peritoneum, mesentery, and broad ligament (Figure 2).9  
  
5 
 
Figure 1. Model of EOC dissemination 
Unlike classic metastasis of other epithelial tumors, most EOCs spread by intraperitoneal 
“seeding”. Initially, EOC cells (shown in the figures as red circles) are limited to one or both 
ovaries within the intact ovarian capsule. Once the ovarian capsule is disrupted, tumor cells 
are passively exfoliated by the flow of peritoneal fluid (step 1). Exfoliated tumor cells form 
aggregates to avoid anoikis (step 2). Surviving tumor cells are transported by peritoneal 
fluid and then implant at secondary sites (step 3). 
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Figure 2. Pattern of spread of EOC 
At its earliest stage (stage I), the tumor (shown in the figure as red masses) is limited to one 
or both ovaries. Once the tumor spreads beyond the ovaries, tumor cells directly extend to 
adjacent tissues such as the uterus, the fallopian tubes, the mesothelial lining of the pelvic 
cavity (peritoneum), and the broad ligament (a fold of peritoneum that supports the uterus) 
(stage II). Exfoliated tumor cells are transported by peritoneal fluid and implanted on the 
peritoneum and the mesothelial linings of abdominal organs (serosa) (stage III). Nests of 
tumor cells are commonly observed on the omentum (a peritoneal fold connected to the 
stomach and suspended over the intestines), the mesentery (a peritoneal fold anchoring the 
intestines to the posterior abdominal wall; not shown), and the diaphragm. Ascites is 
commonly associated with intraperitoneal dissemination.  
Adapted with permission from Nat Rev Cancer, Naora, copyright 20059 
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3. Subtypes of EOCs 
 
EOC is not a single disease, but rather comprises a heterogenous group of tumors. 
EOCs are classified into subtypes by their histologic features, with the major subtypes 
being serous, endometrioid, mucinous and clear cell (Figure 3). Each subtype has 
distinctive morphologic and genetic features. Serous EOC, which is the most common 
histologic subtype, exhibits papillary structure and resembles cancers of the fallopian tube 
(Figure 4).11 Serous cancer is divided into low-grade and high-grade subtypes. Although 
they are termed as ‘low-grade’ and ‘high-grade’ serous EOCs, low-grade serous EOCs 
develop through different genetic programs from high-grade serous EOC. Low-grade 
serous EOCs are characterized by the mutations of KRAS, BRAF, and ERBB2 (Table 3).12-
14 In contrast, high-grade serous EOCs are characterized by TP53 mutation, without 
mutations of KRAS, BRAF, and ERBB2 (Table 3).15, 16  Therefore low-grade serous EOCs 
and high-grade serous EOCs are considered as different subtypes of EOCs. Endometrioid 
EOCs resemble cancers of the uterine corpus, whereas mucinous EOCs are composed of 
endocervical-like or intestinal-like cells (Figure 4). Clear cell EOCs are composed of cells 
with clear cytoplasm containing glycogen. The main genetic alterations often found in each 
subtype are summarized in Table 3.  However, the role of these genetic alterations in the 
unique morphologic features of the EOC subtypes has not been conclusively demonstrated.  
  
8 
 
Figure 3. Relative frequencies of subtypes of EOCs             
Relative frequency of subtypes of EOCs based on two relatively recent population-based 
studies.17, 18 Serous is the most common subtype of EOCs and followed by endometrioid 
and clear cell which occur with approximately equal frequency. Mucinous EOCs are less 
common. 
  
Serous 
68-71% 
Clear cell 
12-13% 
Endometrioid 
9-11% 
Other 
7% 
Mucinous 
3% 
9 
 
Figure 4. Müllerian-like morphological features of EOCs 
(A) Hematoxylin–eosin-stained section of normal human ovary surrounded by monolayered 
epithelium (arrow) and containing an inclusion cyst (i.c.). (B) Sections of clinical specimens 
of EOCs: serous, with papillary features; endometrioid, with glandular features; and 
mucinous, with mucin-rich cytoplasm. (C) Sections of normal human fallopian tube, 
endometrium and endocervix. Bar, 50µm 
Adapted with permission from Expert Rev Mol Med, Naora, copyright 200711 
  
A 
B 
C 
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Table 3. The main molecular genetic alterations in different subtypes of EOCs 
 Subtype Gene Frequency References 
Serous 
EOCs 
Overall serous 
EOCs 
BRCA1/2 
PTEN 
PIK3CA 
<10% 19, 20 
High-grade 
TP53 ~80% 15, 16 
CCNE1 ~30% 21 
Low-grade 
KRAS 
BRAF 
ERBB2 
~30% 12-14 
Endometrioid 
EOCs 
CTNNB1 33% 22-25 
PTEN 14 - 21% 26, 27 
PIK3CA ~20% 20, 28 
Mucinous 
EOCs 
KRAS ~50% 29-31 
Clear cell 
EOCs 
PIK3CA 48% 28 
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B. ABERRATIONS OF HOMEOBOX GENES IN HUMAN CANCER 
 
Homeobox genes were originally identified as master regulatory genes controlling 
segment identity in Drosophila. Antennapedia gene is one of the most well-known examples. 
Loss-of-function mutations in the regulatory region of this gene induce the formation of 
ectopic antennae, rather than legs.32 Conversely, gain-of-function mutations cause 
antennae to ectopic legs transformation.32 Homeobox genes encode a family of 
transcription factors which contain a highly conserved DNA binding domain known as the 
homeodomain (Figure 5). This domain forms three alpha-helixes that bind DNA elements 
containing TAAT core motifs.32 The homeobox gene superfamily comprises more than 200 
genes that are categorized into different families based on the similarity of their 
homeodomains.33, 34 Homeobox genes play essential roles in controlling skeletal patterning, 
limb formation, and development of various organ systems including the central nervous 
system and gastrointestinal tract.35-38 Homeobox genes also play important role in adult 
tissues. For example, homeobox genes regulate in vascular remodeling and angiogenesis. 
39 Homeobox genes also control self-renewal as well as lineage specification of 
hematopoietic stem cells.40  
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Figure 5. The structure of the homeodomain 
Transcription factors encoded by homeobox genes are characterized by their highly 
conserved 61 amino acid DNA-binding domain termed the homeodomain. The 
homeodomain forms three alpha helixes (colored boxes) that bind DNA elements 
containing TAAT core motifs. Crystal structure of the Pdx1 homeodomain in complex with 
DNA (PDB ID: 2H1K; crystal structure was visualized by PyMOL.  
 NH2 COOH    H1 H2 H3 
Homeodomai
Helix 1 
Helix 2 Helix 3 
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1. Genomic organization of mammalian homeobox genes 
 
Whereas most homeobox gene families such as the Nkx, Dlx and Msx families 
contain between two and nine genes, the HOX family which is the most extensively studied 
homeobox gene family has 39 members in mammals. Members of HOX gene family are 
organized in clusters. Eight HOX genes in Drosophila are organized in a single 
chromosome. However, the 39 members of the HOX family in mammals are grouped in 
clusters of nine to thirteen genes on four different chromosomes (Figure 6).41 Since these 
four copy of HOX gene clusters (called HOXA-D) have been postulated to derive from gene 
duplication during evolution.42 HOX paralogs which occupy the same relative positions on a 
given chromosomal cluster (e.g., HOXA9, HOXB9, HOXC9 and HOXD9) share greater 
homeodomain sequence similarity than do different members of a single cluster. During 
embryonic development, HOX genes are activated sequentially relative to their physical 
positions along the four genomic clusters. HOX genes at the 3’ end of the clusters are 
generally expressed early in development and in anterior regions, whereas those at the 5’ 
end of clusters are expressed later and in more posterior regions.43 This expression pattern 
is responsible for controlling segmental identity and morphology on the anterior-posterior 
axis. Because of sequence similarities as well as similarities in expression patterns, HOX 
paralogs exhibit some functional redundancy. 
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Figure 6. Conserved genomic organization of HOX genes 
(A) Drosophila has eight HOX genes, arranged in a single cluster, whereas human beings 
have 39 HOX genes arranged in four clusters that are located on different chromosomes. 
Vertebrate HOX groups 1, 2, 4, 5, 6, 7, and 8 are most similar to drosophila labial (lab), 
proboscipedia (pb), deformed (Dfd), sex combs reduced (Scr), antennapedia (Antp), 
ultrabithorax (Ubx), and abdominal-A (Abd-A), respectively. Group 3 is probably specific to 
vertebrates. Groups 9 to 13 are all related to drosophila abdominal-B (Abd-B).  
(B) In both invertebrates and vertebrates, HOX genes control patterning of the embryo 
along the anterior-posterior axis. 
Adapted with permission from The Lancet, Goodman, copyright 200341 
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2. Aberrant expression of homeobox genes in cancers 
 
Homeobox genes have been reported to be expressed aberrantly in a wide variety 
of cancers.  Some examples of aberrant expression of homeobox genes in cancers are 
summarized in Table 4. The expression pattern of homeobox genes in cancers can be 
divided into two broad categories.44 First, homeobox genes that are expressed only during 
embryonic development and not in adult tissues are often up-regulated in cancers. For 
example, PAX2 is normally expressed during kidney development but not in adult kidney. 
But it is reactivated in renal cancer.45-48 Conversely, homeobox genes that are expressed in 
normal adult tissues tend to be down-regulated in cancers. Nkx3.1, which control 
morphogenesis of the prostate, is a good example. Nkx3.1 is expressed in fetal and adult 
prostate tissues,49 but it is frequently deleted in prostate cancers.50 Although several HOX 
genes are reported to be activated by chromosomal translocation in leukemia,51 the 
mechanisms that induce aberrant expression of homeobox genes in solid tumors are 
largely unknown.  
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Table 4. Examples of deregulated homeobox genes in tumors 
 
Gene 
Tumor 
type 
Deregulation 
in cancer 
Effect References 
Nkx 3.1 
Prostate 
Cancer 
 
Homozygous/heterozygous NKX3.1 
mutant mice develop PIN. 
49, 50, 52, 53 
CDX2 
Colon 
cancer 
 
Overexpression promotes differentiation of 
intestinal cells, while leading to reduced 
proliferation and tumorigenicity. 
Heterozygous mutant mice are 
predisposed to colon cancer. 
54-56 
HOXB13 
Prostate 
cancer 
 
Loss of expression inhibits differentiation; 
allows transactivation of AR and 
proliferation. 
57, 58 
HOXA5 
Breast 
cancer 
 
Loss of expression correlates with loss of 
p53 expression. HOXA5 is a transactivator 
of the p53 promoter. 
59 
HOXB7 
Melanoma 
Ovarian 
Breast 
cancer 
 
Promotes tumor growth and angiogenesis 
by inducing expression of FGF-2. Induced 
EMT and promotes DNA repair. 
60-63 
HSIX1 
Breast 
cancer 
 
Overexpression abrogates the G2 cell 
cycle checkpoint in response to X-ray 
irradiation. 
64 
PAX2 
Renal 
cancer 
 
Expressed in renal cell carcinomas. 
Promotes cancer cell survival. 
46-48 
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3. Significance of homeobox genes in EOCs 
 
EOCs have been thought to arise from the simple monolayered ovarian surface 
epithelium (OSE). However, the major EOC subtypes exhibit morphological features that 
resemble those of the Müllerian-duct-derived epithelia (Figure 4). This has led to 
considerable speculation that EOCs originate from Müllerian epithelia rather than the OSE. 
An alternative hypothesis has been that the Müllerian-like morphological features of EOCs 
involves inappropriate activation of genes that normally regulate the differentiation of the 
Müllerian ducts. Study of Cheng et al.65 has implicated aberrant HOX gene expression as 
being responsible for the morphologic features of EOCs.  The mammalian Hoxa9, Hoxa10 
and Hoxa11 genes are uniformly expressed along the axis of the Müllerian ducts prior to 
differentiation, but their expression becomes spatially restricted in the fallopian tubes, 
uterus, and lower uterine segment, respectively.65-68 This Müllerian HOX gene program is 
not expressed in normal OSE, but is recapitulated in EOCs according to the patterns of 
Müllerian-like differentiation of these tumors. Moreover, differential activation of HOX genes 
in transformed OSE cells induces tumors with distinct Müllerian-like features. Transformed 
mouse OSE cells expressing Hoxa9 formed serous-like tumors, whereas those with 
Hoxa10 and Hoxa11 formed endometrioid-like and mucinous-like tumors, respectively 
(Figure 7).65 Other homeobox genes that control urogenital patterning also appear to be 
associated with the morphologic features of EOCs. It has been reported that PAX2 and 
PAX8 are prevalently expressed in non-mucinous EOCs, whereas CDX2 expression is 
restricted to mucinous EOCs.69-74 However, the significance of aberrant expression of 
homeobox genes to the progression and clinical behavior of EOCs is unknown. 
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Figure 7. Control by HOX genes of Müllerian differentiation  
The ovarian surface epithelium and Müllerian ducts derive from the embryonic coelomic 
epithelium. As the Müllerian ducts differentiate to form the fallopian tubes, uterus, cervix, 
and upper vagina, HOX gene expression becomes spatially restricted. These patterns of 
HOX expression are recapitulated in serous, endometrioid, and mucinous EOCs according 
to their patterns of Müllerian-like differentiation.  
Adapted with permission from Expert Rev Mol Med, Naora, copyright 200711 
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C. CANCER-ASSOCIATED FIBROBLASTS (CAFs) 
 
It is increasingly recognized that the crosstalk between tumor cells and surrounding 
stroma cells is important for tumor progression. Tumor progression is dependent on 
angiogenesis75-77 and immune system.78, 79 Fibroblasts comprise the non-vascular, non-
epithelial and non-inflammatory component of the connective tissue80 and have also been 
recognized as a prominent modifier of tumor progression. 
 
  
1. Origins of CAFs 
  
Cancer associated fibroblasts (CAFs) are heterogeneous cell populations that 
reside in the tumor microenvironment. CAFs are distinguished from normal quiescent 
fibroblasts by their expression of markers such as α-smooth-muscle actin (αSMA), 
fibroblast-activated protein (FAP), fibroblast-specific protein-1 (FSP1/S100A4), neuron-glial 
antigen-2 (NG2), and PDGF β-receptor.81 Multiple cell types have been identified as 
potential sources of CAFs (Figure 8).82 Primarily they seem to be derived from local 
resident fibroblasts. However, it has been reported that up to 25% of CAFs originate from 
bone-marrow derived mesenchymal stem cells (MSCs) in mouse xenograft models of 
pancreatic cancer.83 Normal epithelial cells and/or cancer cells derived from epithelial cells 
can be another source of CAFs by undergoing epithelial-to-mesenchymal transition 
(EMT).84, 85 Additionally, some CAFs can derive from endothelial cells. In experimental 
mouse models, cells co-expressing αSMA or FSP1 and the endothelial cell marker CD31 
have been reported. Forty percent of FSP1+ cells and 11% of αSMA+ cells also expressed 
CD31 in a melanoma tumor model.86 Other cell types including tissue-resident MSCs and 
adipocytes have also been proposed as progenitors of CAFs (Figure 8). 
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Figure 8. Origin of CAFs  
Local tissue-resident fibroblasts or bone marrow-derived MSCs are recruited into the 
developing tumor and Müllerian acquire a CAF phenotype. CAFs have also been suggested 
to originate from epithelial or endothelial cells through epithelial/endothelial–mesenchymal 
transition. 
Adapted with permission from Curr Opin Genet Dev, Ostman, copyright 200982 
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2. The role of CAFs in tumor progression 
 
Whereas normal stromal cells tightly restrict outgrowth of epithelial cells, it has been 
demonstrated that CAFs promote the growth of various cancers, including pancreatic, 
breast and gastric cancers.87-89 Conversely, targeting of CAFs inhibits cancer growth.90 The 
interactions between CAFs, tumor cells and other host cells are dynamic, and are controlled 
by a complex network of mediators as described below (Figure 9).91 
 
2.1. Interaction between CAFs and cancer cells 
 
CAFs can directly stimulate cancer growth by producing growth factors such as 
hepatocyte growth factor (HGF), epidermal growth factor (EGF) and IL-6.92, 93 CAFs also 
stimulate migration of tumor cells. CAFs secrete extracellular matrix (ECM) degrading 
proteases such as metalloproteases (MMPs)94, 95 and pro-migratory ECM component such 
as tenascin.96 In addition, CAFs can promote tumor cell migration by releasing various 
growth factors such as TGFβ97 which induce tumor cells to undergo EMT .98, 99 
  
CAFs have also been demonstrated to induce tumorigenesis in specific contexts. 
Olumi et al. reported that non-tumorigenic, immortalized prostate epithelial cells gave rise to 
tumors when co-injected into mice with CAFs.100 In contrast, no tumor formation was 
induced when the prostate epithelial cells were co-injected with normal fibroblasts.100 In 
addition, there is evidence that CAFs promote stem cell-like features in cancer cells. When 
colon cancer cells were cultured with CAFs or conditioned medium from CAFs, cancer cells 
became more stem cell-like with increased nuclear β-catenin expression.101 
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Figure 9. Functions of CAFs  
CAFs communicate with cancer cells, resident epithelial cells, endothelial cells, pericytes 
and inflammatory cells through the secretion of growth factors and chemokines.  
Adapted with permission from Nat Rev Cancer, Kalluri, copyright 200691 
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2.2. Interaction between CAFs and endothelial cells 
 
CAFs have also been demonstrated to drive tumor growth and progression by 
stimulating tumor angiogenesis. Orimo et al. reported that Ras-transformed breast cancer 
cells develop larger tumors when co-injected with CAFs rather than with normal fibroblasts 
and attributed the enhanced tumor growth to increased tumor angiogenesis.88 These 
authors also demonstrated that CAF-derived CXCL12 (also known as stromal cell derived 
factor-1) stimulates recruitment of bone-marrow derived endothelial progenitors to tumors.88 
CAFs are also major sources of vascular endothelial growth factor (VEGF) and MMPs, 
which can increase angiogenesis.102, 103  
 
2.3. Interaction between CAFs and immune cells 
 
The tumor stroma also contains a diverse variety of immune cells including 
macrophages and T cells. Tumor-associated macrophages (TAMs) are major components 
of the leukocyte infiltrate in many solid tumors. Unlike classic cytotoxic macrophages, TAMs 
are often characterized by anti-inflammatory functions and promote tumor growth by 
producing a number of cytokines and growth factors. TAM accumulation is associated with 
poor prognosis in patients with breast, prostate, and bladder cancers.104-106 CAFs stimulate 
the accumulation of TAMs by producing monocyte chemotactic protein 1 (MCP-1, also 
known as CCL2) which is the most well-characterized chemotactic factor for TAMs. MCP-1 
also suppresses the proliferation and activation of CD4+ T cell.107 In addition, CAFs 
produce other immune-modulatory cytokines such as interferon-γ, interleukin-6, and tumor 
necrosis factor-α,108 which influence the recruitment of cytotoxic T lymphocytes, natural 
killer cells and macrophages.  
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D. HYPOTHESIS AND SPECIFIC AIMS 
 
The high lethality of EOC is due to rapid and aggressive peritoneal involvement. 
EOCs frequently colonize peritoneal surfaces that overlie connective and adipose tissues. 
However, the mechanisms that enable EOC cells to readily adapt to the peritoneal 
environment are poorly understood. The goal of my research is to determine the molecular 
mechanisms that control the aggressive behavior of EOCs. 
 
HOXA9, a homeobox gene that is normally expressed in the developing female 
reproductive tract, has been previously found to be aberrantly expressed in EOCs and to 
control the morphologic features of these tumors. The differentiation pattern of a tumor is an 
important determinant of its clinical behavior and prognosis. However, the significance of 
HOXA9 to the clinical behavior of EOC is not known. My broad over-arching hypothesis is 
that HOXA9 promotes the aggressive behavior of EOC. Specifically, I hypothesize that 
HOXA9 promotes the aggressive behavior of this disease by modulating interactions 
between EOC cells and stromal cells.
 
The specific aims of my thesis project are: 
1) To evaluate whether HOXA9 is associated with poor outcomes in EOC patients and in 
mouse intraperitoneal xenograft models of EOC 
2) To determine whether HOXA9 modulates cellular interactions in the EOC 
microenvironment 
3) To characterize the molecular mechanisms of HOXA9 in promoting progression of EOC 
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CHAPTER 2: MATERIALS AND METHODS 
 
 
 This chapter was reproduced with permission of AMERICAN SOCIETY FOR CLINICAL 
INVESTIGATION in the format Republish in a thesis/dissertation via Copyright Clearance 
Center from the following journal article:  
Ko SY, Barengo N, Ladanyi A, Lee JS, Marini F, Lengyel E, and Naora H.  
HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts.  
  J Clin Invest. 2012, 122(10), 3603-17 
 
 
1. Bioinformatic and statistical analyses  
 
Statistical analysis was performed using STATISTICA6 software (StatSoft Inc.). 
Values of statistical significance of data in in vitro and in vivo assays were calculated by the 
Student t-test. Data represent mean + SEM. Correlation coefficients were determined by 
Spearman test. P values >0.05 were considered not significant. Gene expression data from 
EOC patients at the Peter MacCallum Cancer Center (AOCS study) (GSE9891, n = 285) 
were downloaded from the National Center for Biotechnology Information Gene Expression 
Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo). Gene expression data from 
TCGA project (n = 567) were downloaded from the TCGA data portal site (http://tcga-
data.nci.nih.gov/tcga/). Gene expression data were generated by using Affymetrix 
microarray platforms (U133 v2.0 for AOCS, U133A for TCGA). All data were normalized by 
using the robust multi-array average method.109 Where there were multiple probe sets for 
an individual gene, the mean value for the given gene for each case was used. Patients 
were stratified according expression of a given HOX gene, where transcript levels for the 
given gene were defined as High (≥ upper quartile) and Low (≤ lower quartile). Association 
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of expression of a given HOX gene with patient survival was assessed in upper and lower 
quartile sub-groups by using Kaplan-Meier plot analysis and Log-rank test. Transcript levels 
of a given HOX gene were compared between cases that were categorized by clinical 
parameters and significance of differences between groups were estimated by using Mann-
Whitney U-test. 
 
 
2. Source of human tissue specimens  
 
Studies using human tissue specimens and cells were approved by the Institutional 
Research Boards of the University of Texas MD Anderson Cancer Center and University of 
Chicago. Archived specimens of human EOC tissues, that were not necessary for diagnosis 
and were de-linked from patient-identifiers, were obtained from the gynecologic tumor 
banks at the University of Texas MD Anderson Cancer Center and University of Chicago 
with informed patient consent. All cases were Stage III/IV serous EOC. Fibroblasts were 
isolated from normal omental tissues of women undergoing surgery for benign conditions 
as previously described with informed patient consent.110  
 
3. Cell culture 
 
3.1. Primary human cells  
 
Primary cultures of normal human omental fibroblasts were maintained in DMEM 
medium (Invitrogen) containing 10% FBS and MEM Non-essential amino acids. Normal 
human bone marrow MSCs were provided through the Tulane Center for Gene Therapy, 
MSC cell distribution center (Darwin Prockop, Tulane University) and cultured in α-MEM 
27 
 
medium (Invitrogen) containing 20% FBS. Normal human adipose MSCs isolated from 
lipoaspirate were purchased from American Type Culture Collection (ATCC) and cultured in 
MSC basal medium with growth supplement (ATCC). Immortalized, non-tumorigenic human 
ovarian surface epithelial cells (TNOE072) were provided by Jinsong Liu (MD Anderson 
Cancer Center). 
 
3.2. Mouse cells  
 
Stable mouse EOC (MOSEC) lines are described in previous studies65 and were 
cultured in DMEM medium containing 10% FBS. Immortalized mouse endothelial cells111 
were cultured in DMEM containing 10% FBS. L929 mouse skin fibroblasts were purchased 
from ATCC and cultured in Eagle’s MEM medium (Invitrogen) containing 10% FBS.  
 
3.3. Human EOC cell lines  
 
The serous EOC line SKOV3ip and clear-cell EOC line ES-2 were cultured in 
McCoy’s 5A medium (Invitrogen) containing 10% FBS.  
 
4. Transfection 
 
pGFP-V-RS HOXA9, TGF-β2 and non-targeting shRNA plasmids and TGF-β2 
cDNA were purchased from OriGene Technologies. SKOV3ip, ES-2 and MOSEC cells 
were transfected with plasmids by using FuGENE6 reagent (Roche) and selected with 
puromycin (0.5 µg/ml). 
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5. In vitro cell growth assays 
 
EOC cells were seeded either directly on plastic surfaces or embedded in 2% 
Matrigel (BD Biosciences) in 96-well plates (2,000 per well). Cell proliferation was 
measured daily by the 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) 
assay (Roche). To assay cell viability under reduced serum conditions, EOC cells were 
seeded in 12-well plates (2x104 per well), cultured for 3 days in medium containing 0.2% 
FBS and stained with trypan blue dye. To assay colony formation, EOC cells were seeded 
in 6-well plates (2x104 per well) and cultured for 2 weeks in 0.3% agar. Three independent 
experiments were performed for each assay. 
 
6. Stimulation of cells with conditioned media 
 
To generate tumor-conditioned media, EOC cells (1.5x106) were seeded in 10 cm 
dishes and cultured in medium containing 1% FBS for 2 days. Tumor-conditioned medium 
was filtered, assayed by ELISA, and applied to fibroblasts and MSCs. Conditioned medium 
was replaced every 2 days, and cells analyzed by quantitative RT-PCR and Western blot at 
5 days thereafter. For fibroblast-priming assays, fibroblasts were incubated in tumor-
conditioned medium for 5 days and then washed. Fresh non-conditioned medium was 
added and fibroblasts cultured for 2 days. Medium conditioned by fibroblasts was filtered, 
assayed by ELISA, and applied to EOC cells. Growth of EOC cells were measured by the 
MTT assay. Endothelial cell growth was likewise assayed following culture in media 
conditioned by EOC cells and by primed fibroblasts. Conditioned media was depleted of 
CXCL12, IL-6 and TGF-β2 by Immunoprecipitation using antibodies to these growth factors. 
Three independent sets of each type of conditioned medium were evaluated in each assay.  
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7. Co-culture assay 
 
Fibroblasts (1,000) were seeded with 1,000 cells of each GFP expressing EOC line 
per well in 96-well plates. Numbers of fibroblasts (GFP-negative cells) in each well were 
counted daily under light and immunofluorescence microscopy. Three independent 
experiments were performed for each assay. 
 
8. Xenografts 
 
All animal studies were performed at the University of Texas MD Anderson Cancer 
Center with approval of the Institutional Committee on Use and Care of Animals. Four-
week-old female nude mice (purchased from National Cancer Institute) were used for 
animal studies. Mice were inoculated intraperitoneally with cells of MOSEC (1.5x106), 
SKOV3ip (2x106) and ES-2 (1x106) lines or subcutaneously with cells of SKOV3ip (1x106) 
and ES-2 (6x105) lines. For survival studies, mice were euthanized by CO2 asphyxiation 
when morbid ascites had developed. Volumes of subcutaneous tumors were calculated 
from perpendicular measurements of tumor diameters taken daily using calipers. GFP-
expressing intraperitoneal xenografts were visualized in euthanized mice under a Leica 
MZML III fluorescence stereomicroscope.  
 
9. Antibodies and other reagents 
 
Antibodies were purchased from commercial sources as follows: αSMA (Dako), 
CD34 (Abcam), Ki-67 (Vector Laboratories), GFP (Molecular Probes); HOXA9 antibody for 
western blotting (Millipore) and for chromatin immunoprecipitation (Santa Cruz 
Biotechnology), TGF-β2, CXCL12, IL-6 (R&D Systems), FLAG, MYC (Sigma-Aldrich), 
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secondary antibodies (Invitrogen). Recombinant growth factors were purchased from the 
following sources: TGF-β1 (Sigma-Aldrich), TGF-β2, VEGF and IL-6 (Invitrogen). 
 
10. Immunohistochemistry  
 
Formalin-fixed, paraffin-embedded sections of mouse and human tissues were used 
for staining with hematoxylin-eosin and with HOXA9, αSMA, Ki-67, CD34 and TGF-β2 
antibodies. Staining was detected by streptavidin-biotin-peroxidase and 3, 3’-
diaminobenzidine (Dako). Staining using Alexa Fluor-conjugated antibodies was performed 
on frozen tissue sections. Evaluation of staining with each antibody is described in the 
figure legends.  
 
11. Western blotting 
 
Cell extracts were prepared by lysing cells in M-PER buffer (Pierce Biotechnology). 
Total cell lysates were separated by SDS-PAGE, then transferred to PVDF membrane (GE 
Healthcare) and blocked with 5% nonfat milk in TBS with 0.1% Tween-20 (TBS-T). 
Membranes were hybridized with primary antibodies overnight at 4˚C then washed with 
TBS-T buffer. Secondary antibody was incubated with membrane for 1 hour at room 
temperature. Membrane washed with TBS-T buffer was visualized with ECL western 
blotting detection reagent (Amersham Biosciences). 
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12. ELISA 
 
ELISAs kits were purchased from R&D Systems (to detect mouse TGF-β1 and 
human IL-6, CXCL12, VEGF-A, TGF-β1, TGF-β2) and LifeSciences Advanced 
Technologies (for mouse TGF-β2). Levels of each growth factor were assayed according to 
the manufacturer’s instruction in three independent sets of each type of conditioned 
medium and normalized to total cellular protein content. 
 
13. Quantitative RT-PCR  
 
Total RNA was extracted using PureLink RNA mini kit (Invitrogen) following 
manufacturer’s instructions. Purified total RNA (1µg) was used to synthesize cDNA using 
the RT2 First Strand Kit (SABiosciences). Transcripts were analyzed by using 
SYBR®Green qPCR Master Mix (SABiosciences) and primers listed in Tables 5-7. Levels 
of target transcript were normalized to ribosomal protein RPL32. 
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Table 5. Human specific primers for quantitative RT-PCR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Sequence 
ACTA2 
Forward CTATGCCTCTGGACGCACAACT 
Reverse CAGATCCAGACGCATGATGGCA 
FAP 
Forward GGAAGTGCCTGTTCCAGCAATG 
Reverse TGTCTGCCAGTCTTCCCTGAAG 
TGFB1 
Forward GCCCTGGACACCAACTATTG 
Reverse CGTGTCCAGGCTCCAAATG 
TGFB2 
Forward AGAGTGCCTGAACAACGGATT 
Reverse CCATTCGCCTTCTGCTCTT 
VEGFA 
Forward TTGCCTTGCTGCTCTACCTCCA 
Reverse GATGGCAGTAGCTGCGCTGATA 
IL6 
Forward CAATCTGGATTCAATGAGGAGAC 
Reverse CTCTGGCTTGTTCCTCACTACTC 
CXCL12 
Forward CTCAACACTCCAAACTGTGCCC 
Reverse CTCCAGGTACTCCTGAATCCAC 
SNAI1 
Forward GCTGCAGGACTCTAATCCAGAGTT 
Reverse GACAGAGTCCCAGATGAGCATTG 
SNAI2 
Forward ATGAGGAATCTGGCTGCTGT 
Reverse CAGGAGAAAATGCCTTTGGA 
TWIST1 
Forward GGACAAGCTGAGCAAGATTCAGA 
Reverse TCTGGAGGACCTGGTAGAGGAA 
ZEB1 
Forward GGCATACACCTACTCAACTACGG 
Reverse TGGGCGGTGTAGAATCAGAGTC 
ZEB2 
Forward AATGCACAGAGTGTGGCAAGGC 
Reverse CTGCTGATGTGCGAACTGTAGG 
KLF8 
Forward CCTGAAAGCTCACCGCAGAATC 
Reverse TGCTTGCGGAAATGGCGAGTGA 
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Table 5. Human specific primers for quantitative RT-PCR (continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Sequence 
PDGFA 
Forward CAGCGACTCCTGGAGATAGACT 
Reverse CGATGCTTCTCTTCCTCCGAATG 
PDGFB 
Forward GAGATGCTGAGTGACCACTCGA 
Reverse GTCATGTTCAGGTCCAACTCGG 
CXCL1 
Forward GCCAGTGCTTGCAGACCC 
Reverse GATGCTCAAACACATTAG 
CXCL2 
Forward CGCAGCAGGAGCGCC 
Reverse TGGATGTTCTTGAGGTGAATTCC 
TNF 
Forward CCCAGGGACCTCTCTCTAATCA 
Reverse GCTACAGGCTTGTCACTCGG 
FGF2 
Forward AGCGGCTGTACTGCAAAAACGG 
Reverse CCTTTGATAGACACAACTCCTCTC 
RPL32 control primer 
Forward ACAAAGCACATGCTGCCCAGTG 
Reverse TTCCACGATGGCTTTGCGGTTC 
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Table 6. Mouse specific primers for quantitative RT-PCR 
  
Gene Sequence 
Tgfb1 
Forward TGATACGCCTGAGTGGCTGTCT 
Reverse CACAAGAGCAGTGAGCGCTGAA 
Tgfb2 
Forward TTGTTGCCCTCCTACAGACTGG 
Reverse GTAAAGAGGGCGAAGGCAGCAA 
Vegfa 
Forward CTGCTGTAACGATGAAGCCCTG 
Reverse GCTGTAGGAAGCTCATCTCTCC 
Il6 
Forward TACCACTTCACAAGTCGGAGGC 
Reverse CTGCAAGTGCATCATCGTTGTTC 
Rpl32 control primer 
Forward GGAGAAGGTTCAAGGGCCAG 
Reverse TGCTCCCATAACCGATGTTTG 
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Table 7. Human/Mouse common primers for quantitative RT-PCR 
 
 
Gene Sequence 
HOXA9 
Forward CCCTGACTGACTATGCTTGTGGT 
Reverse TCTCCGCCGCTCTCATTCTC 
RPL32 control primer 
Forward CCTTGTGAAGCCCAAGATCG 
Reverse TGCCGGATGAACTTCTTGGT 
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14. Chromatin Immunoprecipitation and reporter assays  
 
Chromatin immunoprecipitation assays were performed using the EZ-ChIP 
chromatin immunoprecipitation Assay kit (Upstate Biotechnology) following manufacturer’s 
instructions. Briefly, cells were cross-linked by adding formaldehyde to 1% final 
concentration at room temperature for 10 minutes. Formaldehyde was then quenched by 
adding glycine and then cells were harvested. Cross-linked genomic DNA was sonicated to 
generate DNA fragment of 200-1000 base pair in length and then performed 
Immunoprecipitation with normal IgG or HOXA9 antibody. DNA was purified from 
precipitated complexes and used to amplify fragments of the TGF-β2 promoter. Fragments 
of the Tgfb2 promoter described in the text were also amplified from mouse genomic DNA 
and cloned into the pGL3 luciferase reporter vector (Promega). Luciferase activities were 
assayed using the Dual-luciferase reporter assay kit (Promega). Primers used for chromatin 
immunoprecipitation and subcloning are listed in Tables 8 and 9. 
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Table 8. Primers for chromatin immunoprecipitation 
 
Primer Sequence 
Mouse primer set for S1 
(-1144bp~-944bp) 
Forward TGTATGCCAGCTATATCATT 
Reverse TGGCCACGATGACTACACAG 
Mouse primer set for S2 
(-784bp~-584bp) 
Forward AGTTTGAGCAAGTTGAAGTA 
Reverse CTCTGTATCACTGCTTTGAA 
Mouse primer set for S3 
(-524bp~-324bp) 
Forward ACAGGGCTGGATTGTAAACA 
Reverse AGGCGTGTACACACACACAC 
Mouse primer set for S4 
(-174bp~+74bp) 
Forward ATGCCAGTCGCCCTCCCTTA 
Reverse AAACCTGCTGCCAGCAGATA 
Mouse primer set for S5 
(+832bp~+980bp) 
Forward CAGATCAGCCACTCCGCACCG 
Reverse GGGGGGAATCTCTCACTTTAAGG 
Mouse primer set 
for Gapdh 
Forward CCATTTTGTCTACGGGACGA 
Reverse GGCCACGCTAATCTCATTTT 
Human primer set for S4 
(-1007bp~-882bp) 
Forward GGTCTAAGTAACGAGAGGACTTC  
Reverse CCAGCAGATAACATCACGATC 
Human primer set for S5 
(+77bp~+227bp) 
Forward CAGATCCGCCACTCCGCACCC 
Reverse GGGAACCCTGACTTTGGCGAG 
Human primer set 
for GAPDH 
Forward TACTAGCGGTTTTACGGGCG 
Reverse TCGAACAGGAGGAGCAGAGAGCGA 
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Table 9. Primers for Tgfb2 promoter construct 
 
 
  
Primer Sequence 
Primer set for region A 
Forward ATGCCAGTCGCCCTCCCTTA 
Reverse GGGGGGAATCTCTCACTTTAAGG 
Primer set for region B 
Forward AGGAGAAGCTAGCGAAGGGTGC 
Reverse CGAATTGAAGCTTCCGCGGT 
Primer set for region C 
Forward GGTATCGGCTAGCTTGATATCCAC 
Reverse GACTCGCAAGCTTCCCTAGC 
Primer set for mutant 
region C 
Forward TATGGGATCCCCCCGCCACGTGT 
Reverse ACGTGGTTTGGGGATCCCGGCTGACGCTCTGCTCC 
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CHAPTER 3: HOXA9 PROMOTES GROWTH OF EOC 
 
This chapter was reproduced with permission of AMERICAN SOCIETY FOR CLINICAL 
INVESTIGATION in the format Republish in a thesis/dissertation via Copyright Clearance 
Center from the following journal article:  
Ko SY, Barengo N, Ladanyi A, Lee JS, Marini F, Lengyel E, and Naora H.  
HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts.  
  J Clin Invest. 2012, 122(10), 3603-17 
 
A. RATIONALE 
 
EOC is the most lethal gynecologic disease in the United States. Seventy percent 
of EOC patients have advanced disease at the time of diagnosis and their five-year-
survival rate is only 20% (Table 2). Unlike other epithelial cancers, EOC readily disperses 
throughout the peritoneal cavity without vasculature involvement. EOC cells are exfoliated 
from their primary site by the circulating peritoneal fluid  and then directly implant on to 
secondary sites, in particular the omentum and surfaces of other abdominal organs 
(Figures 1 and 2).9 However, the mechanisms that enable EOC cells to readily adapt to the 
peritoneal environment are poorly understood. 
 
Cheng et al previously identified a broad trend in expression of Müllerian HOX gene 
program in the major subtypes of EOC according to the patterns of Müllerian-like 
differentiation of these tumors (Figure 7).65 However, the functional significance of 
Müllerian HOX genes to the clinical behavior of EOC is not known. The goal of my studies 
in this chapter is to determine whether Müllerian HOX genes have any impact on the 
clinical outcomes of EOC patients and promote EOC growth in mouse xenograft models. 
  
40 
 
B. RESULTS 
 
1. HOXA9 expression is associated with poor overall survival of EOC patients 
 
I initiated this study by evaluating the clinical significance of Müllerian HOX genes in 
EOCs in the Australian Ovarian Cancer Study (AOCS) gene expression dataset.112 AOCS 
dataset is one of the most comprehensive EOC datasets and contains total 285 cases, of 
which 71% are serous EOCs. In this dataset, it was found that HOXA9 transcript levels did 
not significantly differ between serous carcinomas of ovarian, tubal, and peritoneal origin 
or between serous and endometrioid EOCs, whereas HOXA10 and HOXA11 levels were 
higher in endometrioid than in serous EOCs (Table 10). These observations were 
consistent with previous findings of HOX protein levels in an independent cohort.65 
 
To determine whether HOXA9 expression is associated with poor survival of EOC 
patients, I divided all cases in AOCS dataset into three groups based on the levels of 
HOXA9 transcript: HOXA9-High (≥ upper quartile, n=72), HOXA9-Low (≤ lower quartile, 
n=72) and HOXA9-Medium group (n=141). Compared to the overall survival rates of 
patients in the HOXA9-Low group, patients in the HOXA9-High group had significantly 
poor overall survival in the AOCS cohort (P = 0.0004 by Log-rank test, Figure 10A). 
Mortality rates of HOXA9-High cases were higher than of HOXA9-Low cases irrespective 
of tumor grade and disease stage (Table 11). High HOXA9 expression was also 
significantly associated with poor survival in the Cancer Genome Atlas (TCGA) EOC 
dataset (P = 0.01, Figure 10B). In contrast, the expression level of other Müllerian HOX 
genes (HOXA10, HOXA11), other neighboring HOXA genes or paralogs of HOXA9 were 
not significantly associated with survival of EOC patients (Figure 11).  
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Table 10. Differences in HOX transcript levels between carcinoma cases in the AOCS 
dataset grouped by histologic subtype and primary site 
Cases in the AOCS dataset112 included serous (n=204) and endometrioid (n=20) ovarian 
carcinoma, and serous tubal (n=8) and peritoneal (n=34) carcinoma. P-value was 
determined by Mann-Whitney U-test. 
Gene Comparison P-value Transcript level 
HOXA9 
serous ovarian  vs serous peritoneal P = 0.26 No difference 
serous ovarian vs serous tubal P = 0.31 No difference 
serous ovarian vs endometrioid ovarian P = 0.21 No difference 
HOXA10 serous ovarian vs endometrioid ovarian P = 0.029 serous < endometrial 
HOXA11 serous ovarian vs endometrioid ovarian P = 0.005 serous < endometrial 
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Figure 10. High HOXA9 expression is associated with reduced survival of EOC 
patients  
Kaplan-Meier plot analysis of overall survival times of patients stratified by transcript level of 
HOXA9 in tumors; HOXA9-Low (lower quartile) and HOXA9-High (upper quartile). P-value 
was calculated by log-rank test. (A) Survival analysis from the AOCS dataset (n=72 cases 
per group) (B) Survival analysis from the TCGA dataset (n=142 cases per group) 
 
                             A 
B 
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Table 11. Mortality rates of HOXA9-Low and HOXA9-High cases in the AOCS dataset 
categorized by tumor grade and disease stage 
 
HOXA9-Low 
Number of cases 
HOXA9-High 
Number of cases 
Tumor grade 
Grade 1 1/10 (10.0%) 0/3 (0%) 
Grade 2 5/19 (26.3%) 10/27 (37.0%) 
Grade 3 10/41 (24.4%) 21/41 (51.2%) 
Disease stage 
Stage I 0/11 (0%) 1/8 (12.5%) 
Stage II 0/6 (0%) 1/4 (25.0%) 
Stage III 15/53 (28.3%) 25/53 (47.2%) 
Stage IV 1/2 (50.0%) 5/6 (83.3%) 
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Figure 11. Other related HOX genes are not associated with patient survival 
Kaplan-Meier plot analysis of overall survival times of patients in the AOCS dataset 
stratified by transcript level of each indicated HOX gene in tumors. For each HOX gene, 
transcript levels were defined as High (≥upper quartile) and Low (≤lower quartile). Each 
group contains 72 cases.  
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2. HOXA9 promotes EOC growth in mouse xenograft models 
 
2.1. Overexpression of HOXA9 promotes EOC growth in mouse xenograft models 
 
To determine whether HOXA9 promotes EOC growth in mouse xenograft models, I 
generated mouse EOC lines (MOSEC) that stably express HOXA9, HOXA10 and HOXA11 
(Figure 12). Female nude mice that were inoculated intraperitoneally with +HOXA9 
MOSEC cells developed larger implants than mice inoculated with vector-control MOSEC 
cells (Figure 13). In contrast, the tumor burden of mice that were inoculated 
intraperitoneally with +HOXA10 or +HOXA11 MOSEC cells were not significantly different 
from the vector-control group (Figure 13). Consistent with these observations, mice that 
were inoculated with +HOXA9 MOSEC cells had significantly shorter survival times than 
mice inoculated with vector-control MOSEC cells (P = 0.003, Figure 14A). However, 
survival rates of mice that inoculated with + HOXA10 or HOXA11 MOSEC cells were 
similar to those of mice inoculated with vector-control MOSEC cells (Figures 14B and C). 
These observations were consistent with the association of HOXA9, but not HOXA10 or 
HOXA11, with poor survival of EOC patients (Figure 10 and 11). The increased growth of 
+HOXA9 tumors as compared to +HOXA10 and +HOXA11 tumors was not due to 
differences in ectopic HOX levels between the MOSEC lines (Figure 12), nor due to non-
physiological levels of ectopic expression as the Hoxa9 level in +HOXA9 MOSEC cells 
was within the range of HOXA9 levels detected in EOC clinical specimens (Figure 15).  
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Figure 12. Overexpression of HOX genes  
MOSEC cells were transfected with empty vector and with Myc-tagged Hoxa9, Hoxa10 and 
Hoxa11 cDNAs. Expression level of HOX genes were confirmed by western blot. 
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Figure 13. Growth of intraperitoneal MOSEC xenografts 
Female nude mice were inoculated intraperitoneally with cells of vector-control and HOX-
overexpressing MOSEC lines and sacrificed at 2 months thereafter. (A) Implants on 
peritoneal cavity wall and omentum are indicated. (B) Hematoxylin-eosin-stained tissue 
sections showing implants on the broad ligament. Bar, 200µm 
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Figure 14. HOXA9, but not HOXA10 and HOXA11, promotes tumor growth in mouse 
xenograft models of EOC 
Comparison of survival rates of female nude mice inoculated intraperitoneally with vector-
control and with (A) +HOXA9, (B) +HOXA10, and (C) +HOXA11 MOSEC lines (n=10 per 
group) 
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Figure 15. HOXA9 expression in EOC cells and clinical specimens 
Quantitative RT-PCR analysis of Hoxa9 mRNA levels in MOSEC lines and HOXA9 mRNA 
levels in parental SKOV3ip and ES-2 lines and clinical specimens of EOC. Primers 
recognize both mouse Hoxa9 (MOSEC) and human HOXA9 (SKOV3ip, ES-2, clinical 
specimens).  
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2.2. Knockdown of HOXA9 inhibits EOC growth in mouse xenograft models 
 
To confirm that HOXA9 promotes EOC growth, I evaluated the effect of inhibiting 
HOXA9 expression in human EOC lines. HOXA9 was knocked-down by using shRNAs 
that targeted different sites of HOXA9 (shA9-A and shA9-B). As compared to two negative 
controls (empty vector and Nontargeting shRNA), two HOXA9 shRNAs (shA9-A, shA9-B) 
were equally effective in knocking-down HOXA9 in SKOV3ip and ES-2 cells (Figure 16). 
Expression levels of endogenous HOXA9 in SKOV3ip (serous EOC) and ES-2 (non-
serous EOC) cell lines were similar to those in several EOC clinical specimens (Figure 15). 
Knockdown of HOXA9 markedly inhibited growth of subcutaneous and intraperitoneal 
tumors derived from SKOV3ip and ES-2 lines (Figures 17A-D). 
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Figure 16. Knockdown of HOXA9 in EOC cells 
SKOV3ip and ES-2 cell lines that stably express empty vector, nontargeting shRNA and 
shRNAs targeting different sites of HOXA9 (shA9-A and shA9-B) were generated. 
Expression of HOXA9 was assayed by western blot. 
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Figure 17. Knockdown of HOXA9 inhibits tumor growth in mouse xenograft models 
of EOC 
(A and B) Growth rates of subcutaneous tumors derived from +HOXA9 control (Empty 
vector, Nontargeting) and HOXA9-knockdown (shA9-A, shA9-B) (A) SKOV3ip and (B) ES-2 
lines (n=5 per group). ⃰ P<0.0005 (C and D) Mice were inoculated intraperitoneally with GFP 
expressing (C) SKOV3ip and (D) ES-2 lines and sacrificed at 4 weeks and 20 days, 
respectively. Implants were visualized under a fluorescence stereoscope. Omental implants 
in + HOXA9 control groups are indicated by arrows. Original magnification, ×0.8 
 
 
 
  
A 
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C.  CONCLUSION 
 
The studies in this chapter demonstrate that expression of HOXA9 in EOC cells is 
strongly associated with poor outcomes in EOC patients and in mouse xenograft models of 
EOC. High HOXA9 expression was significantly associated with poor overall survival in 
datasets of two independent cohorts of EOC patients. In addition, the studies showed that 
overexpression of HOXA9 promotes EOC growth, whereas knockdown of HOXA9 inhibits 
EOC growth in mouse xenograft models. In contrast, expression of other neighboring 
HOXA genes or paralogs of HOXA9 is not associated with overall survival in EOC patients. 
Moreover, overexpression of HOXA10 or HOXA11 does not promote EOC growth in mouse 
xenograft models. Together, these findings indicate that HOXA9 promotes EOC growth and 
that this capability is not shared by other related HOX genes. The cellular and molecular 
mechanisms of HOXA9 that promote EOC growth will be the focus of Chapter 4 and 
Chapter 5, respectively. 
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CHAPTER 4: HOXA9 EXPRESSION IN EOC IS  
ASSOCIATED WITH INCREASED ABUNDANCE OF CAFS 
 
This chapter was reproduced with permission of AMERICAN SOCIETY FOR CLINICAL 
INVESTIGATION in the format Republish in a thesis/dissertation via Copyright Clearance 
Center from the following journal article:  
Ko SY, Barengo N, Ladanyi A, Lee JS, Marini F, Lengyel E, and Naora H.  
HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts.  
  J Clin Invest. 2012, 122(10), 3603-17 
 
 
A. RATIONALE 
  
 Tumor growth can be stimulated by a number of genetic alterations. Some genetic 
alterations increase tumor cell proliferation or inhibit tumor cell death by mechanisms that 
are autonomous to the tumor cell. Other genetic alterations can promote tumor growth by 
stimulating non-autonomous mechanisms, such as the interactions between tumor cells 
and the tumor microenvironment. 
 
 Studies in Chapter 3 demonstrated that HOXA9 expression is associated with poor 
survival of EOC patients and promotes EOC growth in mouse xenograft models. The goals 
of the studies in this chapter are 1) to determine whether HOXA9 promotes EOC growth 
by stimulating tumor cell autonomous or non-autonomous processes, and 2) to identify the 
nature of the cellular process that is controlled by HOXA9 in EOC. 
 
 
 
55 
 
B. RESULTS 
 
1. HOXA9 promotes EOC growth in vivo but not in vitro 
 
  As discussed in Chapter 3, HOXA9 promotes EOC growth in mouse xenograft 
models. Consistent with these findings, significantly fewer Ki67+ tumor cells were detected 
in HOXA9-knockdown tumors than in control tumors (P < 0.001, Figure 18). This result 
demonstrates that HOXA9 promotes the proliferation of EOC cells in vivo. However, in vitro 
growth rates of HOXA9-knockdown and control EOC lines were identical, irrespective of 
whether these cells were cultured on plastic, in three-dimensional Matrigel cultures, or 
under serum-deprived or anchorage-independent conditions (Figures 19A-D). Similarly, 
overexpression of HOXA9 increased proliferative activity of MOSEC cells in vivo but not in 
vitro (Figures 20A and B). These findings indicate that HOXA9 does not stimulate EOC 
growth by a tumor cell-autonomous process, but rather that the ability of HOXA9 to promote 
tumor growth depends on interactions with host cells. 
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Figure 18. Effect of HOXA9-knockdown on EOC growth in vivo 
Tumor tissues were collected from mice that were inoculated with SKOV3ip and ES-2 lines. 
Average numbers of Ki-67+ tumor cells per 200x microscopic field were calculated by 
scoring five random fields of stained tissue sections of each mice (n=5 per group). 
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Figure 19. Effect of HOXA9-knockdown on EOC cell growth in vitro 
(A and B) Growth rates of cell lines cultured (A) on plastic and (B) in three-dimensional 
Matrigel cultures were determined by MTT assay. (C) Numbers of viable and non-viable 
cells, determined by exclusion of trypan blue dye, were counted in each well at 3 days after 
culture under serum-deprived conditions. (D) Average number of colonies per 40x 
microscopic field at 2 weeks after culture in soft agar. No significant (n.s.) difference was 
found between cell lines.   
  
A 
B 
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Figure 20. Growth characteristics of MOSEC lines in vitro and in vivo 
(A) Growth rates of cultured MOSEC lines on plastic were measured by MTT assay 
(B) Tumor tissues were collected from mice that were inoculated with MOSEC lines. 
Average numbers of Ki-67+ tumor cells per 200x microscopic field were calculated by 
scoring five random fields of stained tissue sections of each mouse (n=5 mice per group)  
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2. HOXA9 expression is associated with a CAF-like gene signature in clinical 
specimens of EOC 
 
A study by Tothill et al. classified tumors in the AOCS cohort into molecular 
subtypes according to their gene expression signatures and confirmed these subtypes by 
immunohistochemical analysis.112 Of these tumor subtypes, the C1 subtype had the 
poorest outcome and was characterized by a desmoplastic or ‘reactive’ stromal gene 
signature.112 Tumors that were classified as the C1 subtype constituted 39% of cases in 
the HOXA9-High group, but only 4% of the HOXA9-Low group in the AOCS cohort (Table 
12). Conversely, the frequency of the C4 subtype (characterized by a low stromal 
response signature) was higher in the HOXA9-Low than HOXA9-High group (Table 12). 
CAFs are often characterized by their expression of α−smooth muscle actin (αSMA) and 
fibroblast activation protein (FAP).81 Interestingly, expression of ACTA2 (the gene 
encoding αSMA) and FAP was significantly higher in HOXA9-High cases than HOXA9-
Low cases in the AOCS cohort (ACTA2, P = 0.026; FAP, P = 10-7, Figure 21).  
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Table 12. Frequency of molecular subtypes classified by Tothill et al. among HOXA9-
Low and HOXA9-High cases 
Analyzed data from AOCS dataset112 
 
Molecular subtype HOXA9-Low cases HOXA9-High cases 
C1 (reactive stromal signature) 3/72 (4.2%) 28/72 (38.9%) 
C4 (low stromal signature) 14/72 (19.4%) 8/72 (11.1%) 
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Figure 21. HOXA9 expression is associated with increased expression of CAF 
markers in clinical specimens of EOC 
Differences in transcript levels of ACTA2 (the gene encoding αSMA) and FAP between 
HOXA9-Low and HOXA9-High cases in AOCS dataset. P-value was calculated by Mann-
Whitney U-test. In box-and-whisker plots, horizontal bars indicate the medians, boxes 
indicate 25th to 75th percentiles, and whiskers indicate minimum and maximum values.  
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3. HOXA9 expression is associated with increased CAF abundance in mouse 
xenograft models of EOC 
 
To confirm whether HOXA9 expression in EOC is associated with increased 
abundance of CAFs in tumors, αSMA expression was evaluated in mouse xenografts. 
Significantly lower numbers of αSMA+ cells were detected in tumors derived from HOXA9-
knockdown SKOV3ip lines (shA9-A and shA9-B) than in tumors derived from +HOXA9 
control (Empty vector and Nontargeting) SKOV3ip lines (P < 0.0001, Figures 22A and B). 
Identical results were obtained in tumors derived from ES-2 lines (Figure 22A). Conversely, 
abundant αSMA+ cells were detected in +HOXA9 MOSEC tumors but not in vector-control, 
+HOXA10 or +HOXA11 MOSEC tumors (Figure 23). These results suggest that the 
association between HOXA9 and poor survival could be linked to the ability of HOXA9 to 
promote a CAF-rich microenvironment.   
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Figure 22. Knockdown of HOXA9 reduces CAF abundance in mouse xenografts 
(A and B) αSMA expression was evaluated in tumors of mice sacrificed at 20 days after 
inoculation with SKOV3ip and ES-2 lines. (A) The average number of αSMA+ cells per 
1000 tumor cells was calculated by scoring 5 random fields of stained tissue sections of 
each mice (n=5 mice per group) *P<0.0001. (B) Immunofluorescence staining of GFP-
expressing tumor cells (green) and αSMA (red) in tumors of mice inoculated with SKOV3ip 
lines.  Nuclei were visualized by staining with DAPI (blue). Scale bar, 100µm.  
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Figure 23. HOXA9, but not HOXA10 or HOXA11, increases CAF abundance in mouse 
xenografts 
αSMA expression was evaluated in tumors of mice sacrificed at 2 months after inoculation 
with MOSEC lines. Scale bar, 50µm. 
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4. HOXA9 does not induce CAF-like features in EOC cells 
 
A variety of different cell types have been identified as potential sources of CAFs 
(Figure 8).82 Some CAFs can derive from tumor cells that have undergone EMT.81 HOXA9 
might therefore increase the abundance of CAFs in tumors by inducing tumor cells to 
undergo EMT. To test this possibility, I evaluated whether HOXA9 induces EOC cells to 
undergo EMT. The expression level of transcription factors that orchestrate EMT, such as 
SNAI1 (the gene encoding Snail) and SNAI2 (the gene encoding Slug), was not altered by 
HOXA9 in EOC cells in vitro or in vivo (Figures 24A and B). Virtually no overlap was 
observed in xenografts between +HOXA9 EOC cells and αSMA-expressing cells (Figure 
25), indicating that αSMA+ cells did not originate from tumor cells. These findings indicate 
that the increased abundance of CAFs in +HOXA9 tumors is unlikely to be due to the 
trans-differentiation of tumor cells into CAF-like cells.   
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Figure 24. Effect of HOXA9 on expression of EMT-associated genes 
(A) Relative mRNA levels of each indicated gene were assayed by qRT-PCR using human-
specific primers in cultured +HOXA9 control (Nontargeting) and HOXA9-Knockdown (shA9-
B) SKOV3ip lines, and in omental tumors collected from mice that were inoculated with 
SKOV3ip lines (n=5 mice per group). (B) The ability of human- and mouse-specific primers 
to discriminate expression of human (tumor) and mouse (stromal) genes was tested using 
mixtures of RNAs isolated from human EOC cells (SKOV3ip cells) and mouse fibroblasts 
(L929 cells) at different ratios. Shown is heat map analysis of expression (generated by 
Tree View software) where the intensity of red color represents the magnitude of 
expression (log2 scale). 
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Figure 25. αSMA+ cells in mouse xenografts do not derive from tumor cells 
Immunofluorescence staining of GFP-expressing tumor cells (green) and αSMA (red) in 
tumors of mice inoculated with +HOXA9 control (Nontargeting) SKOV3ip and ES-2 lines.  
Nuclei were visualized by staining with DAPI (blue). Scale bar, 50µm.  
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5. HOXA9 expression in EOC cells induces omental fibroblasts to acquire CAF 
features 
 
Another important source of CAFs is normal tissue-resident fibroblasts.88 Because 
EOC frequently involves the omentum, I investigated whether HOXA9 expression in EOC 
cells increases the abundance of CAFs by 1) increasing the numbers of CAF precursor 
cells and 2) inducing normal omental fibroblasts to acquire features of CAFs.  
 
5.1. HOXA9 expression in EOC cells stimulates the expression of CAF markers in 
normal omental fibroblasts 
 
I initially evaluated whether HOXA9 expression in EOC cells increases proliferation 
of tissue-resident fibroblasts. Co-culture assays revealed that HOXA9 expression in EOC 
cells did not affect proliferation of normal omental fibroblasts (Figure 26). In subsequent 
experiments, I evaluated whether HOXA9 increases the abundance of CAFs by inducing 
normal omental fibroblasts to acquire CAF features. To accomplish this, normal omental 
fibroblasts were cultured in medium that had been conditioned by EOC cells that lacked or 
expressed HOXA9 (Figure 27). ACTA2 (the gene encoding αSMA) and αSMA protein 
levels were strongly induced in fibroblasts following incubation (i.e. ‘priming’) in medium 
conditioned by +HOXA9 control SKOV3ip cells but not in medium conditioned by HOXA9-
knockdown SKOV3ip cells (Figures 28A and B). FAP was also more highly induced in 
fibroblasts following priming in medium conditioned by control SKOV3ip cells than by 
HOXA9-knockdown SKOV3ip cells (Figure 28A). To confirm these findings, I evaluated 
omental fibroblasts following priming in medium conditioned by MOSEC cells. Expression of 
αSMA and FAP was more highly induced in fibroblasts following priming in medium 
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conditioned by +HOXA9 MOSEC cells than by parental or vector-control MOSEC cells. 
However, increased induction was not observed when fibroblasts were primed in media 
conditioned by +HOXA10 or +HOXA11 MOSEC cells (Figures 29A and B). 
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Figure 26. Effect of HOXA9 expression in EOC cells on growth rates of fibroblasts 
Normal human omental fibroblasts (1,000 per well) were seeded with cells of the indicated 
GFP-expressing +HOXA9 control and HOXA9-knockdown SKOV3ip lines (1,000 per well) 
in 96-well plates. Numbers of fibroblasts (GFP-negative cells) per well were counted daily 
over a 5 day time course.  
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Figure 27. Diagram of fibroblast-priming assays 
+HOXA9 control and HOXA9-knockdown SKOV3ip cells were cultured for 2 days to 
generate tumor-conditioned media (shown in pink). Normal omental fibroblasts were 
incubated for 5 days in SKOV3ip-conditioned medium (i.e., primed) or nonconditioned 
medium (i.e., unprimed) and then analyzed by western blot and qRT-PCR. Fresh 
nonconditioned medium was added to washed fibroblasts. At 2 days thereafter, medium 
conditioned by fibroblasts (shown in light blue) was analyzed by ELISA and used for 
incubating control (nontargeting) SKOV3ip cells. 
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Figure 28. HOXA9 expression in EOC cells induces expression of CAF markers in 
normal omental fibroblasts  
The expression levels of CAF markers were assayed in omental fibroblasts at 5 days after 
priming in media conditioned by +HOXA9 control and HOXA9-knockdown SKOV3ip cells. 
(A) qRT-PCR analysis of CAF markers. The mRNA level of each gene is expressed relative 
to its level in unprimed fibroblasts (i.e. incubated in nonconditioned medium). (B) Western 
blot of αSMA levels.  
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Figure 29. HOXA9, but not HOXA10 and HOXA11, induces expression of CAF 
markers in normal omental fibroblasts 
The expression levels of CAF markers were assayed in omental fibroblasts at 5 days after 
priming in media conditioned by control and HOX-expressing MOSEC cells (A) qRT-PCR 
analysis of CAF markers. The mRNA level of each gene is expressed relative to its level in 
unprimed fibroblasts (i.e. incubated in nonconditioned medium). (B) Western blot of αSMA 
levels.  
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5.2. HOXA9 expression in EOC cells promotes the ability of fibroblasts to stimulate 
growth of EOC cells 
 
CAFs promote tumor growth by expressing several mitogenic factors for tumor cells 
such as CXCL12 and IL-6.88, 89 In subsequent experiments, I evaluated whether HOXA9 
expression in EOC cells induces normal omental fibroblasts to acquire both molecular and 
functional features of CAFs. Both mRNA and protein levels of CXCL12 and IL-6 were highly 
induced in omental fibroblasts, following priming in medium conditioned by +HOXA9 control 
SKOV3ip cells, but not in medium conditioned by HOXA9-knockdown SKOV3ip cells 
(Figures 30A and B). Fibroblasts that had been primed by control SKOV3ip cells were more 
effective in stimulating tumor cell proliferation than fibroblasts that had been primed by 
HOXA9-knockdown SKOV3ip cells (P < 0.001, Figure 31A). The ability of fibroblasts primed 
by +HOXA9 tumor-conditioned medium to stimulate tumor cell proliferation was blocked 
when fibroblast-conditioned medium was depleted of CXCL12 and IL-6 (Figure 31B). These 
findings indicate that HOXA9 induces tumor-derived factors that stimulate normal 
fibroblasts to acquire CAF features and to express CXCL12 and IL-6 that act in a paracrine 
manner to promote tumor cell proliferation. 
 
These findings were also confirmed in omental fibroblasts that were primed in medium 
conditioned by MOSEC cells. CXCL12 and IL-6 expression was more highly induced in 
fibroblasts following priming in medium conditioned by +HOXA9 MOSEC cells than by 
parental or vector-control MOSEC cells. In contrast, fibroblasts that were primed in media 
conditioned by +HOXA10 or +HOXA11 MOSEC cells showed no significant induction in 
CXCL12 or IL-6 expression (Figures 32A and B). Tumor cell proliferation was more highly 
stimulated by fibroblasts that had been primed in medium conditioned by +HOXA9 MOSEC 
cells than by control MOSEC cells (P < 0.001), whereas priming of fibroblasts in media 
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conditioned by +HOXA10 or +HOXA11 MOSEC cells had little stimulatory effect (Figure 
32C). Again, these findings indicate that HOXA9 induces normal fibroblasts to acquire CAF 
features that stimulate tumor cell proliferation, and that this capability is not shared by 
HOXA10 or HOXA11. 
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Figure 30. HOXA9 expression in EOC cells induces expression of growth factors in 
normal omental fibroblasts  
Levels of growth factors in (A) unprimed and primed fibroblasts, and (B) media conditioned 
by unprimed and primed fibroblasts. (A) qRT-PCR analysis of growth factors. The mRNA 
level of each gene is expressed relative to its level in unprimed fibroblasts (i.e. incubated in 
nonconditioned medium). (B) ELISA analysis to detect growth factors secreted by unprimed 
and primed fibroblasts. *P<0.001; #P<0.005. 
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Figure 31. HOXA9 expression in EOC cells promotes the ability of fibroblasts to 
stimulate growth of EOC cells 
(A) Growth rates of control (Nontargeting) SKOV3ip cells incubated in fibroblast-conditioned 
medium. EOC growth was measured by MTT assay. (B) Relative growth of control 
SKOV3ip cells at 6 days after incubation in medium conditioned by fibroblasts that were 
initially primed in +HOXA9 control SKOV3ip-conditioned medium, where fibroblast-
conditioned medium was left untreated, treated with normal IgG, or depleted by 
immunoprecipitation with antibodies to CXCL12 and IL-6. *P<0.001  
A B 
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Figure 32. HOXA9, but not HOXA10 and HOXA11, promotes the ability of fibroblasts 
to stimulate growth of EOC cells 
(A) qRT-PCR analysis of growth factors in unprimed and primed fibroblasts that were 
primed by MOSEC-conditioned medium. The mRNA level of each gene is expressed 
relative to its level in unprimed fibroblasts. (B) ELISA analysis to detect growth factors 
secreted by unprimed and primed fibroblasts. (C) Growth rates of control SKOV3ip cells 
incubated in medium conditioned by fibroblasts that were primed by MOSEC-conditioned 
medium or left unprimed. 
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5.3. HOXA9 expression in EOC cells promotes the ability of fibroblasts to stimulate 
endothelial cell growth 
 
CAFs promote not only the growth of tumor cells, but also the growth of endothelial 
cells.102, 103 CAF abundance in clinical specimens of EOC has been found to strongly 
correlate with increased microvessel density.113 In subsequent experiments, I investigated 
the effect of HOXA9 expression in EOC cells on endothelial cell growth. Firstly, I evaluated 
microvessel density in mouse xenografts. HOXA9-knockdown SKOV3ip tumors had 
significantly lower microvessel density than +HOXA9 control SKOV3ip tumors (P < 0.005, 
Figure 33A). However, expression of the genes encoding angiogenic factors IL-6 and 
VEGF-A in SKOV3ip cells was not altered by HOXA9 in vitro or in vivo (Figure 33B). On the 
other hand, IL-6 and VEGF-A expression was highly induced in fibroblasts following priming 
in medium conditioned by control SKOV3ip cells but not by HOXA9-knockdown SKOV3ip 
cells (Figures 30A and B). Expression of mouse host cell-derived IL-6 and VEGF-A was 
significantly higher in omental tumors of control SKOV3ip models than in HOXA9-
knockdown tumors (IL-6, P = 0.03; VEGF-A, P = 0.007; Figure 33B). These data suggest 
that HOXA9 expression in EOC cells does not directly promote the growth of endothelial 
cells, but rather activates stromal cells to stimulate endothelial cell growth. 
 
To further evaluate this possibility, growth of endothelial cells was firstly assayed in 
medium that was conditioned by EOC cells that lacked or expressed HOXA9. Endothelial 
cells grew at identical rates when cultured in medium conditioned by HOXA9-knockdown or 
by control SKOV3ip cells (Figure 34A). Secondly, growth of endothelial cells was assayed 
in medium that was conditioned by fibroblasts that had been primed by EOC cells that 
lacked or expressed HOXA9. Endothelial cell growth was more highly stimulated by 
omental fibroblast-derived factors where fibroblasts had been primed in medium 
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conditioned by control SKOV3ip cells than by HOXA9-knockdown SKOV3ip cells (P < 0.005, 
Figure 34B). The ability of medium conditioned by fibroblasts that were primed by HOXA9-
knockdown SKOV3ip cells to stimulate endothelial cell growth was restored when this 
conditioned medium was reconstituted with IL-6 and VEGF-A at concentrations released by 
fibroblasts that were primed by +HOXA9 control SKOV3ip cells (Figure 35). These findings 
strongly suggest that HOXA9 expression in EOC cells promotes tumor microvessel 
formation via inducing normal omental fibroblasts to express IL-6 and VEGF-A. 
 
These results were confirmed in MOSEC xenografts. As compared to vector-control 
tumors, microvessel density was significantly higher in +HOXA9 tumors (P < 0.005) but not 
in +HOXA10 or +HOXA11 tumors (Figure 36A). Expression of HOXA9, but not HOXA10 or 
HOXA11, in MOSEC cells stimulated omental fibroblasts to express IL-6 and VEGF-A 
(Figures 32A and B) and to promote endothelial cell growth (Figure 36B). These results 
demonstrated that ability of HOXA9 to stimulate endothelial cell growth is not shared by 
other Müllerian HOX genes.   
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Figure 33. HOXA9 expression in EOC cells is associated with increased microvessel 
density 
(A) The average number of microvessels per 104 tumor cells was calculated in tumors 
derived from +HOXA9 control (Nontargeting) and HOXA9-knockdown (shA9-B) SKOV3ip 
lines by scoring five random fields of CD34-stained tissue sections of each mice (n=5 per 
group). *P<0.005. (B) Relative mRNA levels of IL6 and VEGFA in cultured SKOV3ip cells 
and those of IL6, VEGFA (in human EOC cells) and Il6 and Vegfa (in mouse host cells) in 
omental tumors of mice that were inoculated with SKOV3ip lines (n=5 mice per group). 
*P=0.03; †P=0.007. P values>0.05 were considered not significant. 
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Figure 34. HOXA9 expression in EOC cells promotes the ability of fibroblasts to 
stimulate endothelial cell growth 
(A) Growth rates of mouse endothelial cells incubated in nonconditioned medium and in 
SKOV3ip-conditioned media. **P < 0.005. (B) Normal omental fibroblasts were left 
unprimed or primed with SKOV3ip-conditioned media (shown in pink) for 5 days. Fresh 
nonconditioned medium was added to washed fibroblasts. Two days thereafter, medium 
conditioned by fibroblasts (shown in light blue) was collected. Growth rates of endothelial 
cells incubated in fibroblast-conditioned medium were measured. *P < 0.005.  
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Figure 35. HOXA9 expression in EOC cells promotes endothelial cell growth by 
inducing normal omental fibroblasts to express IL-6 and VEGF-A 
Growth rates of mouse endothelial cells cultured in medium conditioned by omental 
fibroblasts that were primed by +HOXA9 control (Nontargeting) and HOXA9-knockdown 
(shA9-B) SKOV3ip cells. Where indicated, recombinant IL-6 and VEGF was added to 
medium conditioned by fibroblasts that were primed by shA9-B SKOV3ip cells to achieve 
final concentrations of these growth factors at the same levels as detected in medium 
conditioned by fibroblasts primed by Nontargeting SKOV3ip cells (5000pg/ml for IL-6, 
800pg/ml for VEGF, see Figure 30B). 
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Figure 36. HOXA9, but not HOXA10 and HOXA11, promotes the ability of fibroblasts 
to stimulate endothelial cell growth  
(A) Average numbers of microvessels were calculated in MOSEC-derived tumors by 
scoring five random fields of CD34-stained tissue sections of each mice (n=5 mice per 
group). (B) Growth rates of mouse endothelial cells cultured in medium conditioned by 
omental fibroblasts that were primed by MOSEC-conditioned medium or left unprimed. 
Endothelial cell growth was measured by MTT assays. 
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6. HOXA9 expression in EOC cells induces mesenchymal stem cells to acquire CAF 
features 
 
Mesenchymal stem cells (MSCs) have been studied as a source of CAFs in many 
types of tumors including EOC (Figure 8).87, 89, 114 Bone marrow is the most well-
characterized source of MSCs, but MSCs also reside in most tissues and are abundant in 
white adipose tissues.115, 116 Because EOCs often colonize peritoneal surfaces that overlie 
connective and adipose tissue, I investigated whether HOXA9 expression in EOC cells 
induces CAF features in normal bone marrow-derived MSCs and adipose-derived MSCs. 
As observed in omental fibroblasts, ACTA2, FAP, IL-6, CXCL12 and VEGFA expression 
was highly induced in normal bone marrow- and adipose-derived MSCs following 
incubation in medium conditioned by +HOXA9 control but not by HOXA9-knockdown 
SKOV3ip cells (Figure 37). These results suggest that HOXA9 induces tumor-derived 
factors that stimulate acquisition of CAF features in MSCs as well as in omental fibroblasts. 
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Figure 37. HOXA9 expression in EOC cells induces CAF features in bone marrow- 
and adipose-derived MSCs  
Levels of ACTA2, FAP, IL6, CXCL12, and VEGFA transcripts were assayed in bone 
marrow MSCs and adipose MSCs at 5 days after incubation in media conditioned by 
+HOXA9 control (Nontargeting) and HOXA9-knockdown (shA9-B) SKOV3ip cells. The 
mRNA level of each gene, assayed by qRT-PCR, is expressed relative to its level in MSCs 
incubated in nonconditioned medium.   
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C.  CONCLUSION 
 
The studies in this chapter provide significant insight into the nature of the cellular 
process by which HOXA9 promotes EOC growth. Firstly, I demonstrated that HOXA9 did 
not stimulate autonomous tumor cell growth in vitro. On the other hand, HOXA9 expression 
in EOC cells induced normal omental fibroblasts to express CAF markers. HOXA9 
expression in EOC cells also promoted growth of EOC cells and endothelial cells by 
inducing normal omental fibroblasts to express IL-6, CXCL12, and VEGF-A. My studies 
also demonstrated that this capability of HOXA9 is not shared by HOXA10 or HOXA11. 
Similarly, HOXA9 expression in EOC cells induced normal adipose- and bone marrow-
derived MSCs to acquire CAF features. Together, my studies raise the possibility that 
HOXA9 controls expression of a secreted factor(s) that is released by EOC cells and acts in 
a paracrine manner on normal tissue-resident fibroblasts and MSCs. The molecular 
mechanisms of HOXA9 in this cellular process will be discussed in Chapter 5. 
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CHAPTER 5: EFFECTS OF HOXA9 ON EOC GROWTH ARE MEDIATED 
VIA ITS INDUCTION OF TUMOR-DERIVED TGF-β2 
 
This chapter was reproduced with permission of AMERICAN SOCIETY FOR CLINICAL 
INVESTIGATION in the format Republish in a thesis/dissertation via Copyright Clearance 
Center from the following journal article:  
Ko SY, Barengo N, Ladanyi A, Lee JS, Marini F, Lengyel E, and Naora H.  
HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts.  
  J Clin Invest. 2012, 122(10), 3603-17 
 
 
A. RATIONALE 
 
 Whereas normal stromal cells tightly restrict the outgrowth of epithelial cells, it has 
been demonstrated that CAFs promote the growth of various cancers, including pancreatic, 
breast and gastric cancers.87-89 However, the molecular mechanisms that mediate the 
transition of normal fibroblasts into CAFs are not fully understood.  
 
 In Chapters 3 and 4, I demonstrated that HOXA9 expression is associated with poor 
survival in EOC patients and in mouse xenograft models of EOC. The ability of HOXA9 to 
stimulate EOC growth was found to be primarily due to increased abundance of CAFs in 
tumors. Specifically, it was found that HOXA9 expression in EOC cells induced CAF 
features in normal omental fibroblasts and MSCs. The goal of the studies in this chapter is 
to determine the molecular mechanisms by which HOXA9 induces CAF features in normal 
fibroblasts and MSCs. 
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B. RESULTS 
 
1. HOXA9 induces expression of TGF-β2 in EOC cells 
 
Tumor cells express many growth factors that can stimulate fibroblasts.117-120 To 
determine the molecular mechanism by which HOXA9 induces CAF features in normal 
fibroblasts, I initially evaluated the effect of HOXA9 on expression of fibroblast-stimulatory 
factors in SKOV3ip cells. HOXA9 did not alter expression of genes encoding several 
fibroblast-stimulatory factors such as TGF-β1, which is known to induce transition of normal 
tissue-resident fibroblasts and MSCs into CAFs (Figures 38 and 39).89, 121  However, 
knockdown of HOXA9 significantly down-regulated levels of TGF-β2 mRNA and secreted, 
activated TGF-β2 protein (P < 0.005, Figures 39A and B). Conversely, enforced expression 
of HOXA9, but not HOXA10 or HOXA11, induced TGF-β2 mRNA and protein levels in 
MOSEC cells (Figures 40A and B). In addition, levels of HOXA9 transcripts significantly 
correlated with TGFB2 transcript levels in EOC tissue specimens (R = 0.65, P = 0.00004), 
but no significant correlation was observed for TGFB1 (R = 0.11, P = 0.54) (Figure 41). 
High HOXA9 protein levels were also associated with high TGF-β2 protein levels in clinical 
specimens of omental implants of EOC patients (Figures 42A and B). These findings 
strongly raise the possibility that HOXA9 controls TGF-β2 expression in EOC cells. 
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Figure 38. HOXA9 do not alter expression of genes encoding several fibroblast-
stimulatory factors 
Relative levels of transcripts encoding the indicated growth factors in +HOXA9 control 
(Nontargeting) and HOXA9-knockdown (shA9-B) SKOV3ip lines.  
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Figure 39. Knockdown of HOXA9 suppresses TGF-β2 expression in EOC cells. 
(A) Relative TGFB1 and TGFB2 mRNA levels in SKOV3ip lines. *P < 0.001; **P < 0.005.  
(B) TGF-β1 and TGF-β2 levels in media conditioned by SKOV3ip lines. *P < 0.001.  
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Figure 40. HOXA9, but not HOXA10 and HOXA11, induces TGF-β2 expression in 
MOSEC cells 
(A) Relative level of Tgfb1 and Tgfb2 mRNAs in MOSEC cells. (B) Levels of TGF-β2 in 
media conditioned by MOSEC lines. 
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Figure 41. Levels of HOXA9 transcripts significantly correlate with TGFB2 transcript 
levels in EOC tissue specimens 
Relative HOXA9, TGFB1, and TGFB2 mRNA levels in primary ovarian tumors of 33 cases. 
Correlations were determined by Spearman test.  
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Figure 42. High HOXA9 protein levels are associated with high TGF-β2 protein levels 
in clinical specimens of EOC  
(A) Examples of weak and strong staining of HOXA9 and TGF-β2 in omental tumors of two 
EOC cases, Bar, 100µm. (B) Immunohistochemical staining of HOXA9 and TGF-β2 in 
sections of omental tumors of 18 EOC cases was scored as nil/weak(-/+), moderate (++) or 
strong (+++). Each symbol represents an individual case. 
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2.TGFB2 is a direct transcriptional target of HOXA9 
 
 Because HOXA9 is a transcription factor, I hypothesized that the gene encoding 
TGF-β2 is a transcriptional target of HOXA9 in EOC cells. Five putative HOXA9 binding 
sites were identified in the mouse Tgfb2 promoter (Figure 43A). Binding of ectopic HOXA9 
in MOSEC cells was detected to regions containing two of these sites (S4 and S5) in 
chromatin immunoprecipitation assays (Figure 43B). Binding of endogenous HOXA9 to the 
S4 and S5 sites was detected in +HOXA9 control SKOV3ip cells, but no binding was 
detected in HOXA9-knockdown SKOV3ip cells (Figures 43C and D). These results were 
confirmed by luciferase reporter assay. Luciferase reporter assays using deletion constructs 
of the Tgfb2 promoter demonstrated that the S4 site but not the S5 site was essential for 
HOXA9-induced promoter activity (Figures 44A and B). Activation by HOXA9 through the 
S4 binding site was confirmed in reporter assays by using a Tgfb2 promoter construct in 
which the S4 site was mutated (Figures 44A and B). These results indicate that the gene 
encoding TGF-β2 is a direct transcriptional target of HOXA9.   
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Figure 43. HOXA9 directly binds to TGFB2 promoter 
(A) Representation of the mouse Tgfb2 promoter. Locations of 5 putative HOXA9-binding 
sites evaluated by chromatin immunoprecipitation (S1 to S5) relative to the transcription 
start site (TSS) are indicated. (B) Chromatin immunoprecipitation analysis of interactions of 
FLAG-tagged HOXA9 in MOSEC cells with sites S1 to S5. Immunoprecipitated DNA was 
assayed by qPCR and is expressed as a percentage of total chromatin input. (C) Chromatin 
immunoprecipitation analysis of interactions of endogenous HOXA9 in SKOV3ip cells with 
conserved sites S4 and S5 in the human TGFB2 promoter. The input corresponds to 1% of 
chromatin solution before immunoprecipitation. Immunoprecipitation using cells expressing 
FLAG-tag alone or cells expressing HOXA9 shRNA (shA9-B) as well as 
immunoprecipitation with IgG and amplification of Gapdh and GAPDH as irrelevant genes 
are included as negative controls in B and C. (D) qPCR analysis of immunoprecipitated 
DNA from assays in C, expressed as a percentage of total chromatin input.  
  
 
A 
B 
C D 
97 
 
Figure 44. HOXA9 increases promoter activity of Tgfb2 
(A) Representation of the mouse Tgfb2 promoter. Locations of 5 putative HOXA9-binding 
sites evaluated by chromatin immunoprecipitation (S1 to S5) are indicated. Also indicated 
are the regions evaluated in luciferase reporter assays (pA, pB, pC, pC-mtS4) relative to 
the transcription start site (TSS). Wild-type sequences within the S4 site (in pA and pC) and 
mutant sequences (in pC-mtS4) are shown. (B) Activity of Tgfb2 promoter regions shown in 
A was assayed in +HOXA9 control (black bar) and HOXA9-knockdown (white bar) 
SKOV3ip cells. 
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3. HOXA9 expression in EOC cells also increases stromal TGF-β expression 
 
 TGF-β1 not only induces transition of normal fibroblasts and MSCs into CAFs, but is 
also highly expressed by CAFs.121 I therefore investigated whether HOXA9 expression in 
EOC cells stimulates TGF-β1 expression in omental fibroblasts. Omental fibroblasts that 
were primed in medium conditioned by +HOXA9 control SKOV3ip cells but not by HOXA9-
knockdown SKOV3ip cells had significantly elevated expression of TGF-β1 and also of 
TGF-β2 (P < 0.005, Figures 45A and B). Similarly, TGF-β1 and TGF-β2 were more highly 
induced in fibroblasts when primed in medium conditioned by +HOXA9 MOSEC cells than 
by vector-control, +HOXA10 or +HOXA11 MOSEC cells (Figures 46A and B). TGF-β1 and 
TGF-β2 were also induced in adipose MSCs by +HOXA9 tumor-conditioned medium, 
whereas TGF-β1 but not TGF-β2 was induced in bone marrow MSCs (Figure 47). 
Consistent with the ability of HOXA9 to induce TGF-β2 expression in EOC cells in vitro, 
lower levels of human tumor-derived TGF-β2 were detected in omental implants of mice 
with HOXA9-knockdown tumors as compared to control tumors (Figure 48). Levels of 
mouse host-derived TGF-β2 and TGF-β1 were also significantly lower in omental implants 
of mice with HOXA9-knockdown tumors than of mice with control tumors (Figure 48).  
  
TGF-β1 and TGF-β2 expression was induced in fibroblasts following stimulation with 
recombinant TGF-β1 and TGF-β2 at concentrations released by +HOXA9 tumor cells and 
by fibroblasts primed by +HOXA9 tumor cells (Figure 49A). TGF-β1 and TGF-β2 expression 
in fibroblasts was inhibited when +HOXA9 tumor-conditioned medium was depleted of 
TGF-β2 (Figure 49B). These findings suggest that HOXA9 expression in EOC induces 
autostimulatory production of TGF-β ligands in the stroma. 
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Figure 45. HOXA9 expression in EOC cells induces expression of TGF-β1 and TGF-
β2 in omental fibroblasts 
(A) TGFB1 and TGFB2 mRNA levels were assayed in omental fibroblasts at 5 days after 
priming in media conditioned by +HOXA9 control and HOXA9-knockdown SKOV3ip cells.  
The mRNA level of each gene is expressed relative to its level in unprimed fibroblasts. (B) 
Level of TGF-β1 and TGF-β2 released by unprimed and primed omental fibroblasts. *P < 
0.005; #P < 0.001 
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Figure 46. HOXA9, but not HOXA10 and HOXA11, induces expression of TGF-β1 and 
TGF-β2 in omental fibroblasts 
(A) TGFB1 and TGFB2 mRNA levels in omental fibroblasts that were primed by MOSEC 
conditioned medium or left unprimed for 5 days. The mRNA level of each gene is 
expressed relative to its level in unprimed fibroblasts. (B) Level of TGF-β1 and TGF-β2 
released by unprimed and primed omental fibroblasts.  
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Figure 47. HOX9 expression in EOC cells induces expression of TGF-β1 and TGF-
β2 in MSCs 
TGFB1 and TGFB2 mRNA levels were assayed in bone marrow MSCs and adipose MSCs 
at 5 days after priming in media conditioned by +HOXA9 control and HOXA9-knockdown 
SKOV3ip cells.  The mRNA level of each gene is expressed relative to its level in unprimed 
MSCs. 
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Figure 48. HOXA9 expression in EOC cells induces stromal TGF-β1 and TGF-β2 
expression in vivo 
Relative levels of TGFB1 and TGFB2 mRNAs (in human EOC cells) and Tgfb1 and Tgfb2 
mRNAs (in mouse host cells) in omental tumors of mice that were inoculated with +HOXA9 
control (Nontargeting) and HOXA9-knockdown (shA9-B) SKOV3ip lines (n=5 mice per 
group). Specificity of human- and mouse-specific qRT-PCR primers is shown in Figure 24B. 
*P = 0.025; †P = 0.018. 
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Figure 49. Tumor-derived TGF-β2 induces autostimulatory production of TGF-β 
ligands in omental fibroblasts 
(A and B) Relative levels of TGFB1 and TGFB2 mRNAs in omental fibroblasts at 5 days 
after incubation with (A) recombinant TGF-β1 and TGF-β2 at the indicated concentrations 
and (B) media conditioned by +HOXA9 control SKOV3ip cells, where SKOV3ip-conditioned 
medium was left untreated, treated with IgG, or depleted by immunoprecipitation with 
antibody to TGF-β2. 
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4. Effects of HOXA9 on fibroblasts are mediated by its induction of TGF-β2 
expression in EOC cells 
 
4.1. TGF-β2 recapitulates the stimulatory effects of HOXA9 on fibroblasts in vitro 
 
In subsequent experiments, I investigated whether TGF-β2 recapitulates the 
stimulatory effects of HOXA9 on normal omental fibroblasts and whether the effects of 
HOXA9 could be reversed by inhibiting tumor-derived TGF-β2. TGF-β2 did not alter 
proliferation of fibroblasts (Figure 50). On the other hand, expression of ACTA2, FAP, IL-6, 
CXCL12 and VEGFA was induced in omental fibroblasts following stimulation with 
recombinant TGF-β2 at concentrations detected in medium conditioned by +HOXA9 tumor 
cells (Figure 51A). Conversely, depletion of TGF-β2 from +HOXA9 tumor conditioned 
medium inhibited induction of CAF markers and growth factors in fibroblasts (Figure 51B).  
 
To determine whether the ability of HOXA9 to activate fibroblasts and thereby 
promote proliferation of tumor and endothelial cells is mediated by its induction of tumor-
derived TGF-β2, I evaluated the effects of specifically inhibiting TGF-β2 in +HOXA9 tumor 
cells. Stable expression of TGF-β2 shRNA in SKOV3ip cells (shTGF-β2) decreased the 
TGF-β2 level to the same low level as seen in HOXA9-knockdown SKOV3ip cells (Figure 
52A). In addition, TGF-β2 cDNA was stably expressed in HOXA9-knockdown SKOV3ip 
cells (shA9-B + TGF-β2) to test whether reconstituting TGF-β2 in tumor cells restores the 
effects of HOXA9 (Figure 52A). Neither knockdown nor overexpression of TGF-β2 affected 
growth rates of SKOV3ip cells cultured in nonconditioned medium (Figure 52B). However, 
proliferation of tumor cells and of endothelial cells was less effectively stimulated by 
fibroblast-derived factors when fibroblasts were primed in medium conditioned by TGF-β2-
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knockdown SKOV3ip cells than by control SKOV3ip cells (P < 0.001, Figures 52C and D). 
This reduced stimulation was identical to that observed when fibroblasts were primed in 
medium conditioned by HOXA9-knockdown SKOV3ip cells (Figures 52C and D). 
Conversely, reconstitution of TGF-β2 in HOXA9-knockdown SKOV3ip cells increased the 
ability of fibroblasts to stimulate growth of tumor and endothelial cells (Figures 52C and D). 
These findings indicate that HOXA9 expression in tumor cells promotes the ability of 
fibroblasts to stimulate growth of tumor and endothelial cells by inducing tumor-derived 
TGF-β2 that acts in a paracrine manner on fibroblasts.  
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Figure 50. TGF-β2 does not alter proliferation of fibroblasts 
Growth rates of normal omental fibroblasts treated with recombinant TGF-β2 at the 
indicated concentrations were determined by MTT assay.  
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Figure 51. Tumor-derived TGF-β2 induces molecular features of CAFs in normal 
omental fibroblasts 
(A and B) Relative ACTA2, FAP, IL6, CXCL12, and VEGFA mRNA levels in omental 
fibroblasts at 5 days after incubation with (A) recombinant TGF-β1 and TGF-β2 at the 
indicated concentrations and (B) media conditioned by +HOXA9 control SKOV3ip cells, 
where SKOV3ip-conditioned medium was left untreated, treated with IgG, or depleted by 
immunoprecipitation with antibody to TGF-β2.  
A 
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Figure 52. Tumor-derived TGF-β2 induces functional features of CAFs in normal 
omental fibroblasts 
 (A) TGF-β2 levels released by control (Nontargeting), TGF-β2–knockdown (shTGF-β2), 
and HOXA9-knockdown (shA9-B) SKOV3ip lines and a HOXA9-knockdown line stably 
expressing TGF-β2 (shA9-B + TGF-β2). *P < 0.001. (B) Growth rates of control 
(Nontargeting), TGF-β2–knockdown (shTGF-β2), and HOXA9-knockdown (shA9-B) 
SKOV3ip lines and a HOXA9-knockdown line stably expressing TGF-β2 (shA9-B + TGF-
β2), where cell lines were cultured in nonconditioned medium. (C and D) Growth rates of (C) 
control SKOV3ip cells and (D) endothelial cells incubated in medium conditioned by 
omental fibroblasts that were primed by SKOV3ip-conditioned medium or left unprimed.  
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4.2. Stimulation of EOC growth by HOXA9 in vivo is mediated by its induction of 
tumor-derived TGF-β2 
 
To validate my in vitro findings, I firstly evaluated whether reconstituting TGF-β2 in 
HOXA9-knockdown EOC cells restores the tumor growth-promoting phenotype of HOXA9 
in intraperitoneal mouse xenograft models. As compared to mice inoculated with HOXA9-
knockdown SKOV3ip cells, mice that were inoculated with HOXA9-knockdown SKOV3ip 
cells stably expressing TGF-β2 developed substantially larger tumors (Figure 53A). 
Reconstitution of TGF-β2 in HOXA9-knockdown tumor cells markedly increased mitotic 
activity, abundance of αSMA+ cells and microvessel density in tumors to the levels seen in 
+HOXA9 control tumors (Figure 53B). As compared to mice with HOXA9-knockdown 
tumors, mice with HOXA9-knockdown tumors that stably expressed TGF-β2 had 
significantly shorter survival times (P = 0.003, Figure 53C). The poor survival rate of these 
mice was almost identical to that of the +HOXA9 control group (Figure 53C). Conversely, 
tumor growth was reduced in mice that were inoculated with TGF-β2-knockdown SKOV3ip 
cells as compared to mice with control tumors (Figure 53A). Mitotic activity, αSMA+ cells 
and microvessel density were markedly reduced in TGF-β2-knockdown tumors, as were 
similarly observed in HOXA9-knockdown tumors (Figure 53B). As compared to mice with 
control tumors, mice with TGF-β2-knockdown tumors had significantly longer survival times 
(P = 0.003, Figure 53C). The higher survival rate of mice with TGF-β2-knockdown tumors 
and the reduced size of omental tumors in these mice were very similar to observations in 
the HOXA9-knockdown group (Figures 53A and C).  
 
  To confirm these findings, I evaluated the effect of inhibiting TGF-β2 in +HOXA9 
MOSEC cells in vivo (Figure 54A). As compared to mice inoculated with +HOXA9 MOSEC 
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cells, mice that were inoculated with +HOXA9 MOSEC cells in which TGF-β2 was inhibited 
developed smaller intraperitoneal tumors (Figures 54B and C). Knockdown of TGF-β2 in 
+HOXA9 MOSEC cells substantially reduced mitotic activity, abundance of αSMA+ cells 
and microvessel density in tumors, almost to the levels seen in vector-control MOSEC 
tumors (Figure 54D). Together, these results demonstrated that HOXA9 promotes tumor 
growth by inducing tumor-derived TGF-β2.  
 
In subsequent studies, I evaluated the clinical significance of TGF-β2 expression in 
datasets of EOC patients. When EOC patients were stratified according to expression of 
TGF-β2 in tumors, high TGF-β2 expression was significantly associated with poor overall 
survival (P = 0.005, Figure 55). This association of high TGF-β2 expression with poor 
survival in the AOCS dataset was consistent with the association of high HOXA9 levels with 
poor survival in the same patient cohort (Figure 10), and with observations in mouse 
xenograft models. 
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Figure 53. Reconstitution of tumor-derived TGF-β2 restores the effects of HOXA9- 
knockdown on growth of SKOV3ip xenografts 
(A and B) Female nude mice were inoculated intraperitoneally with SKOV3ip lines and 
sacrificed at 4 weeks thereafter. (A) Implants viewed under a fluorescence stereoscope. 
The arrow indicates the omental implant in the control group. Original magnification, ×0.8. 
(B) The average number of Ki-67+ tumor cells, αSMA+ cells, and microvessels in tumors 
was calculated by scoring 5 random fields of stained tumor tissue sections of each mouse 
(n = 5 mice per group). *P < 0.005; †P < 0.01. (C) Survival rates of mice inoculated 
intraperitoneally with SKOV3ip lines (n = 10 per group). Significance values for each group 
as compared with the Nontargeting control group are indicated.  
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Figure 54. Inhibition of tumor-derived TGF-β2 blocks stimulatory effects of HOXA9 on 
growth of MOSEC xenografts 
(A) TGF-β2 levels released by vector-control and +HOXA9 MOSEC cells, and by +HOXA9 
MOSEC cells stably expressing Tgfb2 shRNA (+HOXA9+shTGF-β2). (B and C) Female 
nude mice were inoculated intraperitoneally with MOSEC lines and sacrificed at 2 months 
thereafter. (B) Omental implants are indicated. (C) Hematoxylin-eosin-stained tissue 
sections showing mesenteric implants. Bar, 200µm (D) Survival rates of mice inoculated 
intraperitoneally with MOSEC lines, where the +HOXA9+shTGF-β2 group was compared to 
vector-control and +HOXA9 groups (n=10 mice per group). (E) The average number of Ki-
67+ tumor cells, αSMA+ cells, and microvessels in omental implants was calculated by 
scoring five random fields of stained tumor tissue sections of each mouse (n = 5 mice per 
group).     
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Figure 55. High TGFB2 expression is associated with poor overall survival of EOC 
patients 
Kaplan-Meier plot analysis of overall survival times of patients in the AOCS dataset 
stratified by transcript level of TGFB2. TGFB2 transcript levels were defined as High (≥ 
upper quartile) and Low (≤ lower quartile) (n = 72 cases per group).  
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C. CONCLUSION 
  
 In this chapter, I determined the molecular mechanisms by which HOXA9 
expression in EOC cells induces normal tissue-resident fibroblasts and MCSs to acquire 
features of CAFs. Firstly, the gene encoding TGF-β2 was identified as a direct 
transcriptional target of HOXA9 in EOC cells. Tumor-derived TGF-β2 was demonstrated to 
induce expression of CAF markers and growth factors in normal omental fibroblasts. My 
studies demonstrated that inhibiting TGF-β2 in +HOXA9 EOC cells substantially blocked 
the stimulatory effects of HOXA9 on CAFs and tumor growth. Conversely, reconstituting 
TGF-β2 in HOXA9-knockdown EOC cells restored the CAF-activating, tumor growth-
promoting phenotype of HOXA9. Together, my results indicate that HOXA9 promotes EOC 
growth by inducing tumor-derived TGF-β2 that acts in a paracrine manner to stimulate the 
ability of fibroblasts to support tumor growth. 
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CHAPTER 6: DISCUSSION 
 
 
A.TGF-β2 IS A KEY EFFECTOR OF HOXA9 ON THE GROWTH OF EOC 
 
My studies in Chapter 3 demonstrated that high HOXA9 expression is associated 
with poor overall survival of EOC patients and that HOXA9 promotes EOC growth in mouse 
xenograft models. My subsequent studies in Chapter 4 demonstrated that HOXA9 
expression in EOC cells promotes tumor growth through a mechanism dependent on host 
stromal cells and not via a tumor cell-autonomous mechanism. Specifically, my studies 
showed that HOXA9 expression in EOC cells induces normal omental fibroblasts and 
MSCs to acquire CAF features that promote growth of tumor cells and endothelial cells. 
Furthermore, my studies in Chapter 5 demonstrated that the tumor growth-promoting ability 
of HOXA9 is mediated primarily through its activation of TGF-β2 expression in EOC cells. 
Several of fibroblast-stimulatory factors, such as PDGF-α and FGF-2, promote fibroblast 
proliferation but do not induce CAF features.122 The negligible effect of HOXA9 on 
expression of these mitogenic factors is consistent with its lack of effect on fibroblast 
proliferation (Figures 26 and 38). On the other hand, TGF-β2 induced CAF features in 
normal fibroblasts and MSCs but did not stimulate proliferation of these cells (Figures 50 
and 51). Although HOXA9 might control other CAF-activating factors, the significance of 
HOXA9-induced TGF-β2 is supported by the ability of TGF-β2 antibody to substantially 
block the stimulatory effect of HOXA9 (Figure 51B). The ability of TGF-β2 to induce CAF 
features in normal omental fibroblasts could explain why normal cells expressing CAF 
markers have been detected in omental tissues of EOC patients without overt omental 
metastasis.123 Because TGF-β2 is a soluble factor, the observed propensity of +HOXA9 
118 
 
tumors for omental involvement might stem from fertilization of the omental “soil” by tumor-
derived TGF-β2. 
 
1. TGF-β2 is a direct transcriptional target of HOXA9 
 
Transforming growth factor-βs (TGF-βs) are multifunctional proteins that control cell 
proliferation, differentiation and other functions in most cell types.124 Three isoforms of TGF-
β (TGF-β1, TGF-β2, TGF-β3) have been reported in mammals. Elevated levels of TGF-β1 
and TGF-β2 proteins have been reported in EOC patients, but TGF-β3 protein was not 
detected.125 TGF-β isoforms share their receptors and activate the same SMAD signaling 
pathways.126 These isoforms therefore share many biological functions.127 In this study, 
TGF-β1 and TGF-β2 were also found to have a similar ability to induce CAF features in 
normal omental fibroblasts (Figure 51A). Whereas TGF-β1 is known to induce CAF features 
in tissue-resident fibroblasts and bone marrow MSCs,89, 121 this is the first study that 
demonstrates the significance of TGF-β2 in promoting CAFs. The most pronounced 
differences in the TGF-βs are their spatially and temporally distinct expression patterns at 
the mRNA and protein levels. My studies in Chapter 5 demonstrated that HOXA9 promotes 
expression of TGF-β2, but not expression of TGF-β1 (Figures 39 and 40A). The different 
isoforms of TGF-β are encoded by different genes located on different chromosomes and 
their promoter organization is remarkably different.128, 129 For example, the TGFB1 gene 
lacks a classical TATA box, whereas TGFB2 contains TATA boxes. The TGFB1 promoter 
contains AP-1, SP-1, NF-1 binding sites, whereas these sites are absent from the TGFB2 
promoter.129 My finding that HOXA9 controls transcription of TGFB2 and not TGFB1 is 
consistent with reports that these genes are differentially regulated in developing tissues, 
regenerating tissues and in pathologic responses.130-132  
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2. TGF-β2 does not act in an autocrine manner in EOC cells 
 
It is well-established that TGF-βs inhibit proliferation of normal epithelial cells by 
stimulating CDK inhibitor expression which leads to G1 arrest.133, 134 However, HOXA9 did 
not inhibit growth of EOC cells (Figures 19A and 20A). Furthermore, overexpression of 
TGF-β2 did not inhibit EOC cell growth (Figure 52B). It is also well-established that TGF-
βs induce EMT in various cell types.135, 136 Because HOXA9 induces TGF-β2 expression in 
EOC cells, it might be expected that +HOXA9 EOC cells undergo EMT. However, HOXA9 
did not alter expression of EMT-promoting transcription factors in EOC cells, even those 
known to be direct targets of TGF-β2137 (Figure 24). Together, these findings indicate that 
tumor-derived TGF-β2 does not act in an autocrine manner in EOC cells. This can be 
explained in several ways. Mutations in genes that encode core components of the TGF-β 
signaling pathway such as the TGF-β receptors and Smad proteins have been identified in 
many cancers including EOCs.138-140 In addition, expression of betaglycan, the co-receptor 
for TGF-β2, is decreased or lost in 73% of high grade EOCs.141 Some proteins that are 
aberrantly expressed in cancers can also block TGF-β signaling. For example, the 
transcription factor encoded by the homeobox gene DLX4 has been found to be highly 
expressed in EOCs and to block both TGF-β-induced growth inhibition and EMT by directly 
binding to Smad proteins.142   
 
3. Tumor-derived TGF-β2 induces autostimulatory production of TGF-βs in the 
stroma 
  
My studies demonstrated that HOXA9 not only directly induces expression of TGF-
β2 in EOC cells, but also leads to increased expression of TGF-β1 and TGF-β2 in omental 
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fibroblasts and MSCs (Figures 45, 46, and 47). TGF-β auto-induction has been recognized 
in wound healing.143 Kojima et al. have reported the existence of a TGF-β autocrine 
signaling loop in the stroma of breast cancer xenograft models.144 However, this earlier 
study did not explain how the TGF-β autocrine signaling loop is initiated in the stroma. My 
studies in Chapter 5 support the existence of a self-sustaining TGF-β autocrine signaling 
loop in CAFs. Moreover, my findings indicate that tumor-derived TGF-β2 induces normal 
fibroblasts to acquire CAF features and initiates TGF-β autocrine signaling loop in CAFs 
(Figure 49). The CAF-stimulatory effects of HOXA9 in EOCs could therefore be amplified by 
surrounding stroma cells through their auto-induction of TGF-β ligands. 
 
B. HOXA9 EXPRESSION IN EOC CELLS ‘EDUCATES’ THE STROMA TO BECOME 
PERMISSIVE FOR TUMOR GROWTH 
 
1. HOXA9 expression in EOC induces CAF features in multiple types of CAF 
precursor cells 
 
The high abundance of CAFs is associated with poor prognosis in many types of 
cancers, including EOCs.145 Recent studies support several potential cellular origins of 
CAFs (Figure 8). In my study, four different cell types were evaluated as potential CAF 
precursors: epithelial tumor cells, normal omental fibroblasts, bone marrow-derived MSCs, 
and adipose-derived MSCs. Because TGF-β signaling induces EMT in many cell types,146 
CAFs in +HOXA9 tumors might derive from epithelial tumor cells. However, HOXA9 did not 
alter the expression of EMT-promoting transcription factors in EOC cells (Figure 24). 
Moreover, my study did not identify CAFs that originated from epithelial tumor cells in 
mouse xenografts (Figure 25). The possibility cannot be entirely excluded that a small 
proportion of CAFs might derive from EOC cells. However, my findings strongly indicate 
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that the majority of CAFs in EOC derive from host cells. Furthermore, my studies in Chapter 
4 demonstrated that HOXA9 expression in EOC cells induces CAF features in all three 
types of host-derived cells (i.e. tissue-resident fibroblasts and MSCs, and more distal, bone 
marrow-derived MSCs). 
 
MSCs reside in most adult tissues, but are particularly abundant in white adipose 
tissues.115, 116 Omental, mesenteric and gonadal adipose tissues are major repositories of 
visceral white adipose tissues and are the most commonly involved sites in EOC.147-149 My 
studies in Chapter 4 showed that adipose MSCs can be more effectively induced by 
+HOXA9 EOC cells than by –HOXA9 EOC cells to acquire CAF features. This finding could 
explain the greater propensity of +HOXA9 tumors to develop large implants on the 
omentum, mesentery and broad ligament. Whereas the number of bone marrow MSCs 
declines with age,149 visceral white adipose tissue increases with age. Because EOC 
commonly occurs in post-menopausal women, adipose MSCs might contribute significantly 
to the EOC stroma.  
 
2. HOXA9 expression in EOC cells induces functional features of CAFs in normal 
omental fibroblasts 
 
 My studies in Chapters 4 and 5 support a model in which HOXA9-induced, tumor-
derived TGF-β2 stimulates normal fibroblasts and MSCs to express CXCL12 and IL-6, 
which in turn acted in a paracrine manner to stimulate tumor cell proliferation (Figures 30 
and 32). Stromal-derived CXCL12 and IL-6 are known to promote tumor cell growth and 
their expression correlates with poor outcomes.88, 150, 151 Moreover, CXCL12 has been 
reported to stimulate migration of MSCs toward tumor cells.89 Increased levels of stromal 
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CXCL12 might also contribute to CAF abundance in +HOXA9 tumors by stimulating MSC 
recruitment.  
 
My studies in Chapters 4 and 5 also support a model in which HOXA9, via its 
induction of tumor-derived TGF-β2, promotes EOC growth by stimulating tumor 
angiogenesis. Inhibiting TGF-β2 in +HOXA9 EOC cells substantially blocked the stimulatory 
effect of HOXA9 on tumor microvessel density (Figure 53B). Conversely, reconstituting 
TGF-β2 in HOXA9-knockdown EOC cells increased tumor microvessel density (Figure 53B).  
Furthermore, HOXA9 expression in EOC cells induced normal fibroblasts and MSCs to 
express VEGF-A and IL-6, which in turn acted in a paracrine manner to stimulate 
endothelial cell growth (Figures 34B and 36B). Because CXCL12 stimulates recruitment of 
endothelial progenitor cells to tumors,88 elevated stromal CXCL12 levels might also 
contribute to increased angiogenesis in +HOXA9 tumors.  
 
C. THE ROLE OF HOXA9 IN TUMOR PROGRESSION 
 
1. HOXA9, but not HOXA10 and HOXA11, promotes EOC growth 
 
 Many homeobox genes have been reported to be aberrantly expressed in a wide 
variety of tumors, but their mechanisms in tumorigenesis are poorly understood. While 
some homeobox genes have been reported to promote angiogenesis in tumors,152, 153 most 
of the homeobox genes studied to date have been found to alter tumor cell proliferation or 
survival in vitro.47, 154, 155 This implies that homeobox genes primarily modulate tumor growth 
via tumor cell-autonomous mechanisms. In contrast, my study demonstrates that a 
homeobox gene that is expressed in tumor cells promotes tumor growth via paracrine 
effects on stromal cells. The mechanisms that underlie aberrant expression of HOXA9 in 
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EOCs are as yet unclear. HOXA9 expression varies widely among EOC patients in the 
AOCS and TCGA cohorts. HOXA9 promoter methylation has been reported in EOCs.156, 157 
However, HOXA9 promoter methylation has been detected at a significantly lower 
frequency in late-stage EOC than in early-stage EOC.157 This is consistent with our findings 
that HOXA9 promotes progression of EOC. 
 
Aberrant expression of HOXA10 and HOXA11 has also been detected in subsets of 
EOCs.65 Some HOX genes have similar functions.158 The HOXA9, HOXA10 and HOXA11 
genes share extensive tracts of homology and are thought to have evolved by gene 
duplication from the same ancestral gene.158 However, my study demonstrated that the 
ability of HOXA9 expression in EOC cells to induce normal fibroblasts and MSCs to acquire 
CAF features is not shared by HOXA10 and HOXA11 (Figures 29 and 32). Interestingly, 
HOXA10 has both tumor-promoting and tumor-suppressing properties. On one hand, 
HOXA10 induces the expression of β3-integrin in immortalized ovarian surface epithelial 
cells and increases their growth by promoting direct contact with fibroblasts.159 On the other 
hand, HOXA10 and β3-integrin also inhibit invasiveness in endometrial cancer cells.160 
Consistent with these prior reports, this study showed a modest increase in mitotic activity 
in +HOXA10 MOSEC xenografts as compared to vector-controls (Figure 20B). However, 
the expression of HOXA10 is not associated with poor survival in EOC patients and mouse 
xenograft model of EOCs (Figures 11 and 14). 
 
2. The role of HOXA9 in other tumors 
 
HOXA9 has been identified as the most highly correlated gene for poor prognosis in 
acute myeloid leukemia (AML).161 HOXA9 expression is normally down-regulated in mature 
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myeloid cells. However, overexpression of HOXA9 in primary bone marrow cells enhances 
hematopoietic stem cell regeneration, blocks differentiation, expands the myeloid progenitor 
cell pool, and collaborates with the Meis1a co-factor to induce AML.162, 163 The exact 
mechanisms of HOXA9 in leukemogenesis are not fully understood, and only a few HOXA9 
target genes have been identified.164 Interestingly, TGF-β2, like HOXA9, is also 
preferentially expressed in primitive hematopoietic cells and stimulates the repopulating 
capacity of hematopoietic stem cells.165 Therefore, it might be possible that HOXA9 controls 
expansion of hematopoietic progenitor cells via its induction of TGF-β2.  
 
Although HOXA9 is a well-characterized oncogene in AML, the role of HOXA9 in 
solid tumors is virtually unknown. HOXA9 is constitutively activated in AML by chromosomal 
translocation t(7;11)(p15;p15), where the nucleoporin gene NUP98 is fused to HOXA9.51, 166 
However, this chromosomal translocation has not been detected in solid tumors. On the 
other hand, HOXA9 has been reported to be down-regulated in breast and lung cancer 
cells.167, 168 HOXA9 has been reported to have tumor-suppressing properties in breast 
cancer by inducing BRCA1 expression.167 It is well-established that HOX genes exhibit 
context-dependent functions in normal development.158 Therefore, HOXA9 might have 
tumor-promoting or tumor-suppressive properties depending on the specific type of tumor. 
 
D. CONCLUSION 
 
It is increasingly recognized that crosstalk between tumor cells and surrounding 
stromal cells is dynamic and essential for tumor growth. Over the past 30 years, numerous 
genes have been identified as important drivers of autonomous tumor cell growth. However, 
molecular aberrations in tumor cells that promote interactions between tumor cells and 
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stromal cells are poorly understood. My study supports a model in which HOXA9 
expression in EOC cells “educates” the stroma to become permissive for tumor growth by 
inducing MSCs and resident fibroblasts to acquire molecular and functional features of 
CAFs that promote tumor growth and angiogenesis (Figure 56). Whereas targeting HOXA9 
is therapeutically challenging, inhibiting its downstream effector TGF-β2 may be a 
promising therapeutic strategy. Anti-TGF-β2 therapies have been developed to circumvent 
immunosuppression in cancer patients.169, 170 In addition, a number of small molecule TGF-
β receptor inhibitors have been evaluated in preclinical models and in clinical trials.171-173 My 
studies raise the intriguing possibility that anti-TGF-β2 therapies or small molecule TGF-
β receptor inhibitors could be used to inhibit CAFs in EOC. This is particularly significant for 
improving outcomes of patients with advanced-stage EOC which is rarely cured by 
conventional chemotherapies.  
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Figure 56. Bidirectional signaling between EOC cells and CAFs 
Control of growth factor expression and interactions between EOC cells, CAFs and 
endothelial cells by HOXA9-induced, tumor-derived TGF-β2. 
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